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 Abstract 
The aim of the thesis was to contribute to the knowledge on chronic 
obstructive pulmonary disease (COPD) with respect to incidence, risk 
factors, prognosis and comorbidities. With the epidemiological approach, 
samples from the general population in Norrbotten and in Västra Götaland 
were analysed. The criterion used was the fixed ratio of the expiratory 
volume in the first second (FEV1) through vital capacity (VC) of below 0.70. 
Incidence of COPD during 7 years was 11.0% and for more severe disease 
(GOLD II-IV) 4.9%. On the basis of incidence risk factors for COPD were 
found to be smoking and age. Prognosis of COPD was studied and we found 
that 46% were still alive after 20 years. Risk for death was associated with 
age, male sex, disease severity and comorbid heart failure and ischemic 
heart disease. COPD severity and low FEV1 were signs for worse prognosis 
as well as symptoms of chronic bronchitis. The best prognosis was found 
among subjects with asthma like phenotype. Heart diseases and 
hypertension were prevalent in COPD, and COPD common among subjects 
reporting heart diseases. Present heart diseases was most pronounced in 
more severe grades of COPD and over 50% reported heart disease, 
hypertension or medication for these diseases in the most severe COPD. In a 
population with almost halved smoking frequency 15 years later COPD 
prevalence was lower, but the pattern of comorbidities in COPD remained 
similar. More severe COPD was found to be associated with low BMI and 
being underweight. Obesity was not more prevalent in COPD compared to 
the general population. 
 
The studies give implications for the clinic. Spirometry should be used 
frequently, and repeatedly, in patients exposed to risk factors and with 
respiratory symptoms. In patients with COPD it is of great importance to 
consider concomitant diseases, particularly heart diseases. Equally important 
is to consider presence of airflow limitation among patients with heart 
diseases. This should have impact on treatment of both heart disease and 
COPD. Although prognosis is impaired among patients with COPD, 
reassurance can be communicated. Reversibility on spirometry should be 
evaluated in order to identify patients with asthma-COPD overlap since it 
may influence treatment. Both underweight and obesity in COPD should be 
identified and attempts to intervene should be considered. Identifying 
impaired lung function, especially in obesity, although not fulfilling COPD 
criterion is imperative. 
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BMI 
 Sammanfattning på svenska 
Kroniskt obstruktiv lungsjukdom (KOL) är en vanlig sjukdom som 
ofta ger besvär med hosta, andfåddhet, nedsatt ork, trötthet och sänkt 
funktionsnivå. Sjukdomen kan leda till förtidig död. Diagnosen ställs 
med hjälp av spirometri, men spirometri används för lite inom 
sjukvården vilket innebär att många inte fått rätt diagnos. 
 
Med spirometri kan man upptäcka luftvägsobstruktion genom att 
ensekundsvolymen, det man blåser ut under första sekunden, FEV1,  
är mer sänkt än den volym man kan andas med, vitalkapaciteten, VC. 
Kvoten mellan FEV1 och VC ska vara mindre än 0,70 för diagnosen 
KOL. De dominerande orsakerna till KOL är rökning och ålder, men  
det finns andra riskfaktorer. KOL kan finnas med andra sjukdomar 
hos en individ. 
 
Syftet med den här avhandlingen är att bidra till kunskapen om KOL 
med avseende på hur många som insjuknar (incidens), riskafaktorer 
för KOL, prognos när man har KOL och sjukdomstillstånd som kan 
finnas samtidigt med KOL. Ansatsen är epidemiologisk och de 
studier som ingår i avhandligen baseras på urval ur den vuxna befolk-
ningen i Norrbotten och i Västra Götaland. 
 
I den första studien analyserades insjuknande i KOL under en period 
av 7 år. 11,0%  insjuknade i KOL och 4,9% drabbades av svårare 
sjukdomsgrad, stadium 2-4 av KOL. Rökning och högre ålder var 
riskfaktorer för att insjukna i KOL. De som hade återkommande 
hosta med slem, ofta pipig andning och andfåddhet vid ansträngning 
mer än jämnåriga, hade hög risk att utveckla KOL. 
 
Den andra studien fokuserade på prognos för de som har KOL. 
Studien visade att nästan hälften av de med KOL fortfarande levde 
efter 20 år. Risk för att dö var högre ålder, manligt kön, svårare grad 
av KOL, samtidig hjärtsvikt och ischemisk hjärtsjukdom. De som 
hade bäst prognos var de med tecken på samtidig astma. 
 
I den tredje studien visas att hjärtsjukdomar och högt blodtryck är 
vanligt bland de som hade KOL, och sjukdomen KOL är vanlig bland 
de som har hjärtsjukdomar. Att ha hjärtsjukdom, hypertoni och 
medicinering för dessa var i studien vanligast vid svårare sjukdoms-
grad av KOL. Över 50% av de med svårast KOL hade  någon 
hjärtsjukdom, högt blodtryck eller medicinering för hjärtsjukdom 
 eller hypertoni. Vid restriktiv lungfunktionsnedsättning är både 
ensekundsvolymen, FEV1, och vitalkapaciteten, VC, sänkt. Studien 
visade att även bland dessa individer är det mycket vanligt med 
hjärtsjukdom och högt blodtryck. 
 
Det finns flera studier som visat att sjukdomem KOL ofta leder till 
undervikt. Men det är omtvistat om det finns ett samband mellan 
KOL och fetma. I den fjärde studien var syftet att analysera om det 
finns ett samband, med undervikt och med fetma. Studien kunde visa 
ett samband med undervikt och KOL, men bara i de svåraste sta-
dierna av KOL. Studien baserades på ett urval ur den allmänna 
befolkningen och fetma hos de med KOL var lika vanligt som I 
befolkningen totalt.  
 
Rökning har minskat i Sverige under senaste årtiondena.  I den femte 
studien analyserades om de förändrade rökvanorna hade  påverkat hur 
många som har KOL och om  förekomsten av samtidig hjärtsjukdom 
och hypertoni bland de med KOL hade ändrats. Andelen som rökte 
var halverad jämfört med den tredje studien, som refererats ovan, 15 
år tidigare. Andelen som hade sjukdomen KOL var också lägre. Men 
samtidig hjärtjukdom, hypertoni och medicinering hos de med KOL 
var rätt oförändrat jämfört 15 år tidigare. 
 
Våra resultat visar att det är viktigt att göra om spirometriunder-
sökningar för personer som utsatts för rökning eller andra riskfaktorer 
för KOL, och som har besvär från luftvägarna, även om den första 
spirometrin är normal.  Prognosen om man har KOL är ganska god, 
men är viktigt att få rätt behandling och framför allt att sluta röka. 
Det är viktigt att tänka på att de som har KOL även kan ha hjärt-
sjukdom eller högt blodtryck och att utreda och behandla samtidig 
hjärtsjukdom. Det är också angeläget att komma ihåg att bland de 
som har hjärtsjukdom är risken att ha KOL hög. Det bör göras 
spirometri så att rådgivning och behandling kan sättas in. Undervikt 
vid KOL är vanligt. Även om fetma inte är vanligare hos de med 
KOL, än i befolkningen, finns fetma även bland de som har KOL och 
det utgör en risk för andra sjukdomar. Insatser kan behöva sätttas in 
för båda tillstånden. 
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Introduction 
Author’s perspective 
This thesis is about Chronic Obstructive Pulmonary Disease (COPD). 
Although an academic text, the writing will uncover a physician’s 
perspective. The academic approach is that of epidemiology where the 
group is analysed with respect to health, diseases, risk factors for diseases 
and prognosis. The focus of epidemiological research is the group, never 
the individual. As a physician my focus is the one patient in front of me. 
The uttermost aim of epidemiological research must be the wellbeing of 
patients. My research and clinical work are thus intertwined. 
The goal of academic research is to find new valid knowledge. My 
perspective could be describes as follows: Research is like a gigantic 
crossword puzzle where single words are written in empty spaces, other 
words are changed. Or as a big canvas where the painting is an 
illustration, which helps understanding our world, and where I can 
contribute with some valuable insertions. 
This thesis gives me the opportunity to summarize my research and to 
give a wider picture of my research and expose my clinical interest. 
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Aim 
Chronic obstructive pulmonary disease (COPD) is a common disease 
often with symptoms, disabilities and untimely death. COPD has not 
been a clear entity and has developed from clinical observations of severe 
disease to be possible to identify by spirometry. Diagnosis is based on 
lung function testing (spirometry) where the ratio of the forced expiratory 
volume in the first second (FEV1) and vital capacity (VC) should be less 
than 0.70, according to international guidelines. Underdiagnosis is a 
common problem in clinical practice most often due to limited utilization 
of lung function testing. The predominant causes for COPD are smoking 
and age; other risk factors are not satisfactorily identified. COPD often 
coexists with other diseases and with deviations from normal weight. 
The overall aim of the present studies is to contribute to the knowledge of 
COPD with focus on incidence, risk factors, prognosis, and 
comorbidities. The particular aims are as follows: 
1. To estimate the cumulative incidence of COPD and risk factors 
related to the development of COPD, including evaluation of the 
relationship between Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) stage 0 (that is respiratory symptoms and 
normal lung function) and the development of COPD, in an age-
stratified general population sample of middle-aged and elderly 
individuals. 
2. To study 20-year outcomes, mainly mortality, in a COPD cohort 
derived from a population study. 
3. To explore the association of COPD and restrictive lung func-
tion impairment, respectively, with heart diseases in the general 
population. 
4. To determine the association between severity grades of airflow 
limitation in COPD, and both underweight and obesity when 
corrected for possible confounding factors. 
5. The aim of the study was to investigate whether the pattern of 
comorbidities had changed in Sweden after decades of decrease 
in the prevalence of smoking. 
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Background 
In the following I will give the background to my research, my 
perception of COPD, as the entity has emerged, and the rationale for my 
research. The delimitation of COPD has changed through history and, to 
a smaller degree, during the research period of the studies in this thesis. 
How many will fall ill of COPD is of value to know for clinician and 
health care provider. Characteristics of individuals, before getting the 
disease, can be important clues to causes of COPD. Although a specific 
prognosis is not possible to establish for the individual patient, knowl-
edge about disease progression is often requested and can provide us with 
a better understanding of the disease. 
The possibility of other diseases present among individuals with COPD is 
of great importance in the clinic and the constituents of comorbid 
associations are not well identified. Nutritional status in COPD is impor-
tant for our understanding of the disease and can be a reason to involve 
the dietician for the patient. 
Smoking is an unhealthy habit. Various efforts have been made in soci-
ety, and by health care workers, to minimize smoking. It is of importance 
to evaluate these efforts with respect to the prevalence of current 
smoking, of COPD, and of an influence on the presence of other diseases 
in COPD. 
COPD - a pulmonary disease 
Breathing, or ventilation, is essential for respiration, which is essential 
for life. We breathe no matter what. Breathing movements start 
episodically in utero, are continuous at birth and, except for the briefest 
of pauses, continue without respite (Feldman et al., 2003)1. 
Pulmonary diseases are numerous. Diseases of the ventilatory system are 
of obstructive or restrictive kind, or both. Obstructive impairment is 
               
1 In this thesis, if there is more than one author, the reference will be to the first 
name followed by et al. This is for increasing readability. In order to highlight 
articles where I have been involved my name is also included in the reference in 
the text. 
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mainly due to compromised airflow as in asthma and in COPD. The 
airflow limitation of asthma is reversible. In COPD the airflow 
obstruction is persistent and not fully reversible. The airflow limitation is 
due to narrowed airways and/or loss of elastic recoil of the lungs. 
Restrictive ventilatory limitation is due to delimited volumes and causes 
for restricted lung volumes are wide-ranging including pulmonary 
diseases, neuromuscular dysfunction, obesity and heart diseases, and 
other factors. 
COPD characteristics 
COPD is a common disease, affecting somewhere about 9 to 10% of 
adult population in the world (Halbert et al., 2006) with high costs for the 
individual and society (Jansson et al., 2002). 
Major definitions of COPD are those of the American Thoracic Society 
(1995), the European Respiratory Society (Siafakas et al, 1995), the 
British Thoracic Society (BTS, 1997), and the adjoined ATS/ERS 
standard (Celli et al., 2004). The Global Initiative for Obstructive Lung 
Disease (GOLD) was published in 2001. The wording may be different 
but the content correspond. The definition of COPD according to GOLD 
(2017) is as follows: 
Chronic Obstructive Pulmonary Disease (COPD) is a common, pre-
ventable and treatable disease that is characterized by persistent respi-
ratory symptoms and airflow limitation that is due to airway and/or 
alveolar abnormalities usually caused by significant exposure to nox-
ious particles or gases (web-site). 
Thus COPD is common, preventable, treatable, and characterised by 
persistent symptoms and airflow limitation. Airway and/or lung tissue 
abnormalities, as consequence of exposure, are the cause of the airflow 
limitation in COPD. A prerequisite for the diagnosis of COPD is a not 
fully reversible ratio of the forced expiratory volume in the first second 
(FEV1) and the forced expiratory volume (FVC) of below 0.70 
(FEV1/FVC<0.70). The GOLD document has a strategic intention, and 
the criterion for COPD according to GOLD is adopted by several 
national societies and implemented in guidelines (NICE, 2010; 
Socialstyrelsen, 2015a). The GOLD versions have been thoroughly 
revised since 2001, mainly in 2006, 2011, and now 2017. 
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The present studies use foremost the criterion of the GOLD workgroup 
with respect to airflow limitation as the fixed ratio (paper I-IV) with other 
criteria in additional analyses (paper IV-V). 
The disease of COPD 
COPD is in the realm of diseases. What comprises a “disease” is, at first 
sight, easy: A disease is the opposite of health. That approach creates 
new questions such as on what health is. A pragmatic view is that disease 
is a condition that affects a person’s wellbeing and prognosis. 
What constitutes a disease has varied over time and in various cultures 
(Scully, 2004). Some conditions have developed into diseases while other 
conditions have disappeared from the realm of disease. Conditions 
previously considered as part of normal ageing are now seen as diseases. 
This change pertains to COPD as well. One of the earliest known de-
scriptions from the realm of obstructive lung diseases is that of Badham 
(1808). The essay arose from clinical observations of patients with very 
severe and often deleterious disease and description contained dyspnoea, 
cough and observation of lungs that did not collapse at autopsy. This 
essay also contains detailed information on medical treatment. Laënnec 
(1834) named and described chronic bronchitis and emphysema, both 
from a clinical and from a pathoanatomical perspective. Chronic bron-
chitis with symptoms of cough and phlegm and emphysema were earlier 
often used as synonyms and later also as synonyms for COPD. 
New diagnostic methods have broadened our view on disease. By means 
of biomarkers we can identify a disease early and often before clinical 
symptoms emerges and maybe never develops. The spirometer was 
invented by Hutchinson (1846), but his device measured only vital capac-
ity with no flow measures. The French physician Tiffeneau (1947) was 
the first to describe time measured lung volumes. The spirometer that 
simultaneously can register volume and time is a necessity for the diag-
nosis of COPD. 
New therapeutic options create new diseases. “Are new disease entities 
being created to match drug development? As the business literature 
shows, new clinical diagnoses are often welcomed primarily as 
opportunities for market growth” (Scully, 2004, p 651). Since COPD 
seems to affects more individuals than, for example diabetes, and is 
possible to treat, at least with respect to symptoms, the disease is of great 
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interest for the pharmaceutical industry. New drugs and devices have 
appeared with benefits for patients with COPD. 
COPD in society 
In December 1952 a severe air-pollution in London resulted in more than 
4,000 deaths and several ten thousand respiratory illnesses. Although not 
initially appreciated by health officials, it is an important starting point 
for research on air pollution and acute and chronic pulmonary diseases 
(Bell et al., 2001; Davis, 2002; Fry et al., 1961). The interest is seen in 
Sweden by publications from SBU (2000), two National guidelines 
(Socialstyrelsen, 2004; 2015a), and The Medical Products Agency 
(Läkemedelsverket, 2015). Health professionals and scientists have been 
engaged in the workgroups but the mission is from the authorities. 
COPD and research 
The first publication with “Chronic obstructive pulmonary disease” is 
from 1960 (Karon et al., 1960). The report from the Mayo clinic certainly 
contains some subjects with COPD, as we define at now, and the study 
included lung function testing with maximal midexpiratory flow rate and 
maximal breathing capacity. There was an attempt to describe the risk 
factor for COPD and smoking was identified. The term COPD, though, 
was used somewhat arbitrary as “emphysema”, “obstructive pulmonary 
disease” and “obstructive emphysema” were used as synonyms. 
A sign of the rising interest in the chronic disease is a symposium, held 
by British researcher in 1958 (Fletcher et al., 1959), which recognized the 
common, and often disabling, disease and acknowledged the confusion 
and misunderstanding in the research field. The definitions delimited 
emphysema from chronic 
non-specific lung disease: 
chronic bronchitis, inter-
mittent airflow obstruction 
and persistent obstruction 
of bronchial airflow. The 
latter can be seen as an 
origin to COPD. Lung 
function test was recom-
mended including FEV1 
and FVC and calculating 
the ratio between these. 
Figure 1. The "Fletcher curve, from Fletcher et al., 1977 (with
permission). 
 BACKGROUND   7
The tests should be done before and after inhalation of a bronchodilator 
aerosol. No guidance was formulated for how to interpret the ratio. 
An important and influential work is the study of Fletcher et al. (1976) 
and the accompanying article in the British Medical Journal in 1977 
(Fletcher et al., 1977). The decline in FEV1, as a marker for the natural 
history of chronic bronchitis, was in focus. The research identified 
smoking as the cause for lowered lung function and suggested that 
neither exacerbations nor chronic bronchitis contributed. A subgroup was 
identified as having obstruction defined as FEV1/SVC (slow vital capac-
ity) below 0.66⅔, comprising about 15% of the study population. The 
study of Fletcher et al has been important and influential in the work 
towards what is now considered COPD. The work, and especially the 
presentation of the curve of FEV1 decline, is often presented as the 
“natural history of COPD”. More correctly it would be “the accelerated 
decline of FEV1 among smokers”. 
Much research, including epidemiological studies, has been performed 
since then with the aims of identifying risk factors for the disease. The 
terms “chronic bronchitis” and “emphysema” were used with different 
content in clinical and research articles and often interchangeable 
(Fletcher et al., 1984). 
Despite the dedicated work on chronic pulmonary disease the uncertainty 
around the definition is mirrored in the following citation from a 
textbook on COPD 1995 (Snider, 1995): 
That the initial chapter of this book is on the definition of chronic ob-
structive lung disease (COPD) reflects not only the confusion that ex-
ists in the field of the obstructive airflow diseases, but also the con-
fusion in nosology and definitions that has historically pervaded all of 
medicine (p. 1). 
The GOLD document from 2001 acknowledges the problems of the 
definition of COPD, and the different usage in clinical and research 
contexts (GOLD, 2001). By the publication, and wide acknowledgment 
of the standard, focus came to be on lung function measured by spi-
rometry. In several aspects this can be seen as a progression for research 
and for the clinic. COPD diagnosis became clearer for the clinician, and 
in research the standardization of diagnosis made research results more 
comparable. 
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The way we now define COPD can be regarded as a new entity with 
respect to previous understanding of, and focus on, chronic bronchitis 
and emphysema. Symptoms of bronchitis, that is recurrent cough and 
phlegm, are rather common in the general population and airflow 
obstruction is not always present. And not all with airflow obstruction 
report symptoms of bronchitis. Similarly emphysema is not always 
accompanied by airflow obstruction and not present in all subjects with 
COPD (GOLD, 2017). 
The disease can be said to have gone from severe symptoms, often with a 
deleterious outcome, to a disease that can be identified by a biomarker, 
spirometry. This provides possibility to diagnose the disease early, 
identify risk factors, give advice regarding life style, and to treat non-
pharmacologically and with medication. This change of focus toward a 
standardization of diagnosis in epidemiology has raised new questions 
and given new challenges for research, whereof some are addressed in 
this thesis. 
Airflow limitation in COPD 
A key issue is the airflow limitation, or chronic obstruction, of COPD. 
Various variables have been used to identify airflow obstruction such as 
FEV1 of reference value (Huhti et al., 1988), forced expiratory time 
(American Thoracic Society, 1995), maximal ventilator volume (Karon et 
Figure 2. Example of normal spirometry, with explanations. 
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al., 1960), and other variables. A pathological ratio of FEV1 versus VC1 
is a prerequisite since mid 1990 (BTS, 1997), but the cut-off level, and 
whether use slow vital capacity (SVC) or forced vital capacity (FVC), for 
a pathological ratio has been varying. Table 1 shows some major 
definitions of chronic obstruction. 
Table 1. Some definitions of airflow limitation in COPD. 
Fletcher 1976 FEV1/SVC< 0.66⅔ 
ATS 1986 FEV1/VC <0.75                   (American Thoracic Society, 1986) 
ERS 1995 FEV1/VC <88% of reference values in men 
FEV1/VC <89% of reference values in women (Siafakas, 1995) 
BTS 1997 FEV1/VC <0.70 and FEV1 <80% of reference value 
ATS 1995 Disease description but no new definitions since 1986 
GOLD 2001 FEV1/FVC <0.70 after bronchodilation  
SLMF 2002 Max FEV1/Max(SVC and FVC) before and after bronchodilation 
<0.70; age>65: <0.65 
NICE 2004 FEV1/VC <0.70 and FEV1 <80% of reference value 
ATS/ERS 2004 FEV1/VC ≤0.70                                                (Celli, 2004) 
ERS 2005 FEV1/SVC<LLN5th                                           (Pellegrino, 2005) 
ERS 2011 FEV1/FVC<LLN5th                                           (Bakke et al., 2011 
The two conflicting views on what constitutes an airflow limitation in 
COPD are the fixed ratio, i.e. a FEV1/FVC<0.70 (GOLD, 2017), and the 
lower limit of normal (LLN5th) criterion (Pellegrino et al., 2005), which 
implies a ratio of FEV1/FVC below the fifth percentile of reference value. 
The first published studies with a fixed ratio of FEV1/FVC<0.70 are from 
two Nordic countries (Bakke et al., 1991; Lange et al., 1989). Attempts to 
validate the two criteria have been performed (van Dijk et al., 2015; 
Vollmer et al., 2009). 
Since 2011 version of GOLD, and in the most recent updated version of 
2017, it is acknowledged that the fixed ratio of 0.70 may carry a risk of 
overdiagnosis of the elderly. In research, for example in epidemiology, 
               
1 VC often denotes slow vital capacity (SVC), but sometimes the highest value of SVC 
and FVC. 
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this would add “noise” to the material by including older subjects without 
other signs or symptoms and without known exposure in old age 
(Quanjer et al., 2010). In the clinical setting the risk of overdiagnosis is 
limited. A larger problem is the underutilization of spirometry (Lindberg 
et al., 2006; Quach et al., 2015), and there are no guidelines advocating 
screening by spirometry among healthy or un-exposed. 
In the latest GOLD version, and since 2011, the LLN criterion is 
discussed, that the LLN criterion is dependent on the choice of valid 
reference equations, and that validating studies for the use of LLN are 
lacking (GOLD, 2011). In the same document the use of VC, i.e. the slow 
vital capacity, is an alternative and the same criterion of FEV1/VC <0.70 
is recommended. 
In order to address an over-diagnosis among elderly the Swedish 
Pulmonary Society previously recommended a fixed ratio of FEV1 to VC 
of below 0.65 for older patients and below 0.70 for other. The ratio 
should be calculated with the highest value of FEV1, SVC and FVC 
before and after bronchodilation (Svensk Lungmedicinsk Förening, 
2002). This recommendation remained up to 2015. In the studies on 
incidence, on prognosis and on comorbidities (paper I-III) we used the 
criterion of SLMF without the 65-years rule, i.e. a fixed ratio of 0.70 for 
all. 
Figure 3. Spirometry with irreversible airflow limitation consistent with COPD. 
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What is in focus in the attempt to identify airflow limitation for the 
diagnosis of COPD is a decision limit. The recommendations are 
established by consensus procedures and based on more deductive 
methods. There is still a need to evaluate the decision limits in research, 
and this ought to include prognosis, other health aspects, and effects of 
interventions and treatment. 
The identification of COPD by airflow limitation is affected by the 
choice of slow and forced vital capacity, pre- and post-bronchodilator 
variables, fixed ratio or the lower limit of normal (LLN), and, for the 
latter, choice of reference values. An illustration of the consequences is 
shown in figure 4. The consequences of using three different criteria for 
airflow limitation in COPD is shown in the figure 4 (adapted from 
Eriksson et al., 2015). As is shown the more inclusive criterion, Max VC, 
does not only include mild COPD, nor mainly subjects without 
symptoms. 
Figure 4. Consequences of using three different criteria for airflow limitation in COPD. Max VC=highest
value of FEV1 /highest value of SVC/FVC, before and after BD; FVC=FEV1/FVC after BD; LLN= 
FEV1/FVC after BD < LLN5th defined by the GLI reference value.  
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COPD disease severity 
The most commonly used variable for assessing disease severity of 
COPD is the level of FEV1 of reference value. This was proposed by the 
GOLD document since 2001, by then into 3 stages. The staging was 
recommended for educational reasons for the purpose of simplicity and 
had not been clinically validated by then (GOLD, 2001), but subsequent 
studies show its validity for prognosis and other health aspects (Soriano 
et al., 2015). The GOLD document of 2001 included stage 0 or subjects 
at risk1 of COPD. At risk denoted persons with symptoms, such as cough 
and dyspnoea, but with a normal FEV1/VC ratio. Stage 0 was abandoned 
in the 2006 document, but all revisions recognize that symptoms of 
cough and sputum production may precede airflow limitation (GOLD, 
2006). From 2011 stage was changed to grade (GOLD, 2011). In the 
2011 document of GOLD a classification into ABCD groups was pre-
sented, based on history of exacerbations, grade of airflow limitation and 
symptom scoring. The purpose was for guiding of treatment. FEV1 is 
used for grading of disease severity but is not a variable in the guide to 
treatment (GOLD, 2017). 
Guidelines, and research, suggest that GOLD grades II-IV is a marker for 
more severe disease compared to grade I (BTS, 1997; Antonelli-Incalzi et 
al., 2003, Tsoumakidou et al., 2004). This cut-off limit for more severe 
disease has been used in two of the present studies (paper I and V). We 
have used the LLN criterion as an alternative (paper IV and V), and in 
paper V we used FEV1<LLN for identifying more severe diseases as it is 
more consistent with the LLN model. 
Reference values of lung function testing 
Reference values of dynamic spirometric values are used for diagnosis of 
COPD with the LLN criterion, and for grading of disease severity 
according to the GOLD workgroup and ERS Task force. Reference 
values are not used for the fixed ratio criterion for diagnosis. In the 
Swedish context there has been two somewhat older reference equations: 
Hedenström et al. (1985, 1986), and Berglund et al. (1963). In addition 
the Coal and Steel equations (Quanjer et al., 1993) has been used in the 
clinic. Primarily in treatment studies other reference values, for example 
               
1 ”At risk” in this context represents subjects with a normal FEV1/FVC ratio but 
with symptoms of airway disease. In epidemiology “at risk” denotes the 
“undiseased”, with respect to the disease in focus, in the study sample. 
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NHANES (Hankinson et al., 1999), have been used. Moreover there are 
several national and local reference values. The equations differ due to 
statistical methods and selection of reference population. 
An attempt to create reference 
values as a standard globally 
is the work of the Global 
Lung Function Initiative 
(Quanjer et al., 2012) with 
equations that take ethnicity 
into account. There is some 
support for his view, based on 
observations. This also creates 
some problems. Ethnicity, or 
racial aspects, explains only a minor part of the difference in reference 
values (Harik-Khan et al., 2001). US-born Asians have higher lung 
function compared immigrant Asians (Fulambarker et al., 2010). Two 
Norwegian reference values from nearby areas differ (Langhammer et al., 
2001). Socioeconomic class (Prescott et al., 1999), sitting height 
(Fulambarker et al., 2001) and other variables affect lung function. In a 
world with increasing migration and cross-cultural marriages,  ethnicity 
becomes the more difficult to delimit. 
The OLIN group has calculated reference values based on healthy, non-
smokers in Norrbotten (Backman et al., 2015a). In an evaluation of the 
GLI reference values on a healthy non-smoking cohort in Norrbotten, the 
GLI reference material seemed to represent lower lung function than 
corresponding subjects in Norrbotten. This was most pronounced for 
FVC and among women (Backman et al., 2015b). 
In the studies of this thesis we have used the fixed ratio criterion (paper I 
to V), which is insensitive to reference values for diagnosis. For grading 
we have used Berglund’s reference values (paper I-III), GLI equations 
(paper IV) and the OLIN reference values (paper V). In paper V we used 
both the fixed ratio criterion and the LLN criterion with the OLIN 
reference values. 
Restrictive spirometry 
As the diagnosis of COPD is based on a spirometry with a ratio of FEV1 
to FVC below 0.70, the non-COPD group will contain subjects with low 
Figure 5. From Hutchinson (1846). 
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VC and also low FEV1, that is with a normal ratio but with spirometric 
signs of lung disease or other condition or disease affecting lung 
function. Although restrictive pulmonary disease requires investigation of 
static lung volumes, in order to identify low TLC, a restrictive 
spirometric pattern on dynamic spirometry can indicate symptoms and 
disease. A restrictive spirometric pattern has been defined as FVC below 
80% of reference value (Aaron et al., 1999; Mannino et al., 2008). The 
OLIN studies have also used FVC under LLN for a restrictive pattern 
(Backman, Eriksson et al., 2016a). A restrictive spirometric pattern has 
been shown to have a strong association with hypertension, diabetes and 
cardiovascular disease (Mannino et al., 2003, 2012). 
Figure 6. Spirometry with a restrictive pattern. 
Subjects with a restrictive spirometry can have been included in the cases 
with obstructive lung disease in previous studies when criteria leaned on 
FEV1 only, SVC only, Forced Expiratory Time (FET), or Maximal 
voluntary Volume (MVV). In later studies relying on a pathological ratio 
this group can have been included in the reference group (non-COPD). 
In the present studies (paper III and IV) we used a definition of restrictive 
spirometry as the FVC below 80% of reference value after excluding 
subjects with a FEV1/VC ratio below the decision limit. 
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Symptoms of COPD 
As in most diseases, COPD is accompanied by symptoms. In COPD 
symptoms are described as dyspnoea, wheeze, cough, and phlegm. There 
is a great variation in the expression of these symptoms, and among 
individuals not having COPD report of respiratory symptoms is common. 
Especially dyspnoea is common in the general population, and found in 
several other diseases such as heart failure, asthma, obesity, and other. 
Subjects identified as having COPD, even COPD in more sever grades, 
do not always report or acknowledge these symptoms (Calverley et al, 
2006 p. 7). Particularly subjects with mild COPD often do not report 
chronic symptoms (Kotaniemi et al., 2005). Thus it is not good enough to 
ask: “How does it feel, how does it feel”. More careful inquiries are 
needed in order to identify symptoms of COPD. Several guides are 
possible to use. In the OLIN studies and in the WSAS study questions on 
chronic bronchitis, elaborate questions on wheeze, and on dyspnoea 
according to the Medical Research Council (MRC) recommendations are 
included. 
COPD should be considered in a person with symptoms of breathing,  
and a history of exposure to known risk factors (GOLD, 2016). That 
methodology is good enough for the clinic, and screening patients 
without symptoms is not recommended in most guidelines (U.S. 
Preventive Services Task Force, 2008; GOLD, 2017). Limiting exami-
nations to patients in the clinic with symptoms of breathing will not 
identify all with COPD and might thus miss some who will gain use of 
intervention. In research the aims can be to identify risk factors, provide 
knowledge on prognosis and to find avoidable exposure. Thus restricting 
research to individuals with symptoms might overlook much of important 
information. 
Exposure 
Diseases may be caused by a single factor such as a pathogenic 
microorganism, or a genetic aberration, but more often the cause is 
multifactorial and due to an interaction between the individual and the 
surroundings. Often identified causes do not lead to disease and thus the 
causes can be seen as risk factors for the disease (GOLD, 2017). This 
view implies that the disease is not a random phenomenon. 
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Risk factors, or exposures, are sometimes divided into external, internal, 
and other risk factors. External are current and previous smoking, second 
hand smoke, exposure to biomass fuel, socioeconomic status, occupation, 
environmental pollution, and diet. Internal risk factors include genetic 
factors, gender, and chronic mucus production. Other risk factors include 
airway hyper-responsiveness, asthma, perinatal events and respiratory 
illness during childhood, and recurrent bronchopulmonary infections 
(Vestbo et al., 2016). The only genetic predisposition clearly identified as 
a risk factor for COPD is antitrypsin deficiency (Brode et al., 2012). 
There are reasons to conclude that there is an interaction between host 
predispositions and environmental factors. Up to 50% of smokers 
develop COPD (Lundbäck et al., 2003), which means that about 50% of 
smokers may not develop COPD. A family history of obstructive airway 
disease is identified in some studies as associated with COPD (Kotaniemi 
et al., 2005; Lundbäck et al., 2003). Family history may reflect a genetic 
predisposition but can also represent a broad spectrum of external and 
other risk factors such as socioeconomic factors. 
Suggested risk factors for COPD include: 
• Smoking, current or previous 
• Passive smoking 
• Occupational exposure, foremost gas, dust and fumes 
• Biomass fuel exposure 
• Air pollution 
• Socio-economic status 
• Age 
• Respiratory symptoms 
• Tuberculosis 
• Family history of airway disease 
Several risk factors, or associations, are identified for COPD develop-
ment. None, or several together, do not count for all risks, which leaves a 
statistical randomness. One important aim for research is to minimize 
randomness since this might represent unknown causes. Limiting 
research to known risk factors prevents finding other potential exposures. 
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Smoking 
The research field is unanimous in pointing to smoke as the predominant 
risk factor for COPD, and that relates both to active smoking and former 
smoking with the highest the risk in current smoking. Cigarette smoking, 
as a cause for chronic bronchitis was suggested already in 1955 (Oswald 
et al., 1955; Fry et al., 1961). The study of Fletcher, et al (1976) clearly 
demonstrated the effect of smoking and progressive loss of FEV1. Later 
studies have convincingly established evidence for a forceful impact of 
smoking on the development of COPD (Lundbäck et al., 2003; Stang et 
al., 2000). Passive smoking1 has been seen as a risk factor for COPD 
(Hagstad et al., 2014). The causal inference of smoking for COPD is the 
strongest finding in cross-sectional studies. Incidence studies, based on 
previous definitions of COPD (Heederik et al., 1990; Huhti, 1980; 
Krzyzanowski et al., 1986) and a few new studies based on the fixed ratio 
criterion (Lindberg et al., 2006; Vestbo et al, 2002) gives support to the 
inference of smoking as a cause for COPD. Other risk factors found in 
incident studies have been male sex, exposure to gas, dust and fumes, and 
respiratory symptoms. With respect to these factors the results are 
conflicting. More recent studies (van Durme et al., 2009; Terzikan et al., 
2016) are clear in identifying smoking, and level of smoke exposure, as a 
clear risk factor for COPD. A marked decrease of smoking during more 
than three decades has resulted in a diminished prevalence of COPD, 
especially more severe disease (Backman, Eriksson et al., 2016b). 
Inflammation in COPD 
Inflammatory components have been identified in earlier studies and 
guidelines have suggested that COPD is associated with an inflammatory 
response to noxious gases and particles. Much research has been done on 
smokers, and on clinically identified COPD. The inflammation in COPD 
is not fully understood, and the most recent GOLD revision downplays 
the inflammatory aspect (GOLD, 2017). 
An autoimmune aspect of COPD has been suggested (Kheradmand et al., 
2012). Some patients continue the loss of FEV1 years after quitting 
smoking. On the other hand epidemiological studies show that the group 
that quit smoking restores some of the obstruction (Kohansal et al. 2009; 
               
1 Alternative terms are environmental tobacco smoke, or involuntary smoke 
exposure. 
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Pezzuto et al., 2013). Systemic inflammation in COPD is suggested as 
the connection in the systemic effects of COPD (Vanfleteren, et al. 
2013). 
The research field is challenging since COPD is a diverse disease with 
various causes and different phenotypes. It is reasonable to assume that 
these phenotypes represent different inflammatory responses. 
Treatment 
COPD is a treatable and preventable disease. Prevention is obvious as 
eliminating exposure can limit the progress. The effect of quitting 
smoking was illustrated by Fletcher et al. (1976) and validated in later 
studies (Anthonisen et al., 1994). Important aspects of treatment include 
multidisciplinary rehabilitation and long-term oxygen therapy in respi-
ratory failure (Medical Research Council, 1981; Nocturnal Oxygen Ther-
apy Group, 1980; The Long-Term Oxygen Treatment Trial Research 
Group, 2016). Medical treatment can limit airways symptoms and reduce 
exacerbation frequency. No randomized placebo-controlled studies have 
shown improved prognosis with medical treatment of COPD. First line 
therapy is suggested to be long acting muscarin antagonists (LAMA) or 
long acting beta stimulator (LABA). In more severe grades inhaled 
corticosteroids or dual bronchodilators are suggested as prevention for 
exacerbations (Socialstyrelsen, 2015).  
Asthma and COPD - ACO 
There is a rising interest of the coexistence of asthma and COPD (GOLD, 
2016), and the prevalence seems to be higher than by predictions from 
prevalence of each condition with a statistical overlap (Alshabanat et al., 
2015). The research field is unsettled whether it is a syndrome (ACOS), 
on its own, or two diseases coexisting (ACO). It seems that patients with 
ACO have more severe symptoms (Lee et al., 2016), Most treatment 
studies of either asthma or COPD do not include aspects of the other 
disease and research is needed for this group (Postma et al., 2015). 
Treatment of asthma aims at adequate controller therapy including in-
haled corticosteroids but not long-acting bronchodilators as monotherapy 
while patients with COPD should receive bronchodilators but not inhaled 
corticosteroids as monotherapy (GOLD 2016; Socialstyrelsen, 2015). 
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Both for the clinical setting and the research field measurement of revers-
ibility could be of value in this context. This view is not fully supported 
by the GOLD statement (GOLD, 2017) and the guidelines of the Swedish 
Health Society (Socialstyrelsen, 2015b). 
Conclusion 
COPD has advanced into a disease with a more strict definition although 
there are still some uncertainties. Several areas have not been fully 
described or elucidated. Some of the research questions are addressed in 
the following. 
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Material and Methods 
The present thesis is part of the 
Obstructive Lung disease Studies In Norr-
botten (The OLIN studies) and part of the 
West Sweden Asthma Study (WSAS). 
Both studies have the epidemiological 
approach and the study base is the general 
population from which the study samples 
are recruited. 
Study areas 
Two geographical areas are utilized in the 
present study; Norrbotten, the northern 
most county in Sweden through the OLIN 
studies, and Västra Götaland, the south-
west area of Sweden, through the WSAS 
study. 
The County of Norrbotten has 14 munici-
palities. Norrbotten covers about 24% of 
the area of Sweden but represents only 
about 2.5% of the Swedish population 
(Länsstyrelsen i Norrbotten, 2016). Västra 
Götaland on the other hand has 48 munic-
ipalities and covers about 6% of the area 
of Sweden but represents 17% of the 
Swedish inhabitants (Statistics Sweden, 
2016). 
Figure 7. Study area of the OLIN studies 
(Norrbotten) and of the WSAS study (Västra 
Götaland). 
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Table 2. Descriptive statistics of Norrbotten, Västra Götaland, and Sweden 2015 
(Länsstyrelsen i Norrbotten, 2016; SMHI, 2016; Statistics Sweden, 2016). 
Norrbotten Västra 
Götaland 
Sweden 
Area 97 256 23 797 407 339 
Population 249 733 1 648 682 9 851 017 
Population increase (2000-2015) -6 505 (-2.5) 137 392 (9.1) 968 225 (10.9) 
Foreign background %  10.3 16.8 17.0 
Mean age 43.7 41.0 41.2 
Life expectancy at birth 81.9 82.0 81.9 
Mean income (SKr) 276 022 277 405 282 860 
Mean lowest/highest temperature (°C) -12.2 /+15.41 -0.9 /+16.32  
1. Luleå. 2. Göteborg 
Study design 
The OLIN studies 
The OLIN studies were initiated in 1985 (The OLIN studies, 2016), with 
a postal questionnaire to 6,610 (Lundbäck et al., 1991) individuals living 
in Norrbotten. The OLIN studies have continued with follow-ups with 
questionnaires, interviews, and clinical examinations of both school-
children and adults. New cohorts have been recruited. 
With an epidemiological approach the overall aim of the OLIN studies is 
to prevent obstructive lung diseases (Lundbäck, 1993). The research 
includes epidemiological studies on asthma, type-1 allergies, chronic 
bronchitis, chronic obstructive pulmonary disease, sleep apnoea, and 
health economics. The methods used are cross-sectional, longitudinal, 
case-reference, and clinical studies. In total, more than 50,000 individuals 
aged from 7 to have participated. Today the oldest are 97 years. 
The OLIN studies have also cooperated in several research projects, for 
example in the FinEsS (Finland, Estonia and Sweden) studies, in USA, 
New Zeeland, Vietnam, Italy, and Norway. 
The WSAS study 
The West Sweden Asthma Study was initiated with a postal questionnaire 
sent 2008 to 30,000 randomly selected individuals, 16 to 75 years of age, 
in Västra Götaland.  Over 18,000 responded.  Extensive clinical exami-
nations have been preformed on a randomly selected sample of 2,000 
subjects answering the postal questionnaire and in addition all individuals 
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reporting asthma. In total about 3,600 subjects have been invited to 
clinical examination and interviews. The West Sweden Asthma Study has 
several purposes (WSAS, 2016). The focus is on asthma and a primary 
aim is to investigate the course of prevalence of asthma, respiratory 
symptoms and allergic rhinitis. The study also aims at finding clinically 
relevant main phenotypes of asthma. A third phase is planned consisting 
of laboratory studies of inflammation in asthma and proteomics. The 
primary aims are focused on asthma, but COPD is included, based on 
spirometric tests, questionnaires. 
OLIN cohorts 
The sampling technique of the first two cohorts of the OLIN studies was 
by selecting certain age groups in 8 of the municipalities in Norrbotten. 
Thus in 1985 all inhabitants in the ages 
35-36, 50-51 and 65-66 were recruited. 
A second sample was selected from the 
same area in 1992 in the ages 20-21, 
35-36, 50-51, and 65-66. A third co-
hort was randomly selected also in 
1992 from the same area in ages 20-69 
years. Postal surveys were sent to all 
these individuals. 
These three cohorts are subsequently 
used for random selection and strati-
fied sampling based on respiratory symptoms and examined by means of 
questionnaires, lung function tests and anthropometric measures, while 
subsamples have undergone further investigations.  
The clinically examined subjects from these three cohorts were examined 
in 2002 to 2004, and the pooled material was used for studies on 
association of COPD and BMI (paper IV). 
Figure 8. Municipalities of Norrbotten. 
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Figure 9. The OLIN cohorts of paper I to IV. 
In 1996 a postal questionnaire was sent to a random sample of ages 20-74 
years from the whole county. Ten years later a new investigation of the 
cohort was performed similarly. The same year, 2006, another sample in 
the ages 20-69 years, was selected and examined by means of postal 
questionnaires. After stratification by sex and age a random sample of 
1016 subjects was invited to structured interviews, clinical examinations, 
and spirometry, which started in 2009. 
The OLIN studies contain now 7 adult cohorts and five of these were 
used in the present studies (table 3) (paper I-IV) and also the WSAS 
cohort (paper V). Furthermore two cohorts of schoolchildren, aged 7-8 
years at entry, are involved in longitudinal studies; however these are not 
used in this thesis. 
Response rate 
Table 3 shows response rates of the samples used in the present studies. 
Response rates to postal surveys, and participation rates in clinical 
examinations, were initially high. A slightly weakening trend may be 
seen in the OLIN studies but is obvious in the larger city area of Västra 
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Götaland (WSAS). The response rates in the present studies can be 
judged as high. 
Table 3. Response rates in the cohorts. The studies included in this thesis are 
marked by grey. Cohorts recruited at age 7-8 years are not included. 
Cohort Method Year Invited Response 
rate 
Paper 
OLIN I Postal survey, age-stratified 1985-86 6,610 86.2%  
OLIN I(a) Clinical examination, symptomatics 1986-87 1,655 90.9% II 
OLIN I Postal survey, follow-up 1992-93 6,215 86.7%  
OLIN II Postal survey, age-stratified 1992-93 9,128 84.7%  
OLIN III Postal survey, random sample 1992-93 5,682 85.4%  
OLIN II Clinical examination, symptomatics 1994-95 2,600 76.8%  
OLIN III Clinical examination, random 1994-95 986 67.3% III 
OLIN I Postal survey 1996 5,933 87.5%  
OLIN I(a) Clinical examination, symptomatics 1996-99 1,340 88.2% II 
OLIN I(b) Clinical examination, random 1996-99 1,500 85.5% I 
OLIN I(c) Clinical examination, incident sympt. 1996-99 710 79.4%  
OLIN IV Postal survey, random 1996 8,704 85.2%  
OLIN V Clinical examination, case-control 1995-00 309*2 *  
OLIN I(a) Clinical examination, symptomatics 2002-03 1,082 85.1% I, II, 
IV 
OLIN I(b) Clinical examination, random 2002-03 1,148 85.4% I, II, 
IV 
OLIN I(c) Clinical examination, symptomatics 2002-03 496 82.5% II, IV 
OLIN II Clin. examination, sympt. follow-up 2003-04 1,669 84.4% IV 
OLIN III Clini. examination, random follow-up 2003-04 590 94.1% IV 
OLIN IV Postal survey, random follow-up 2006 7,004 84.1%  
OLIN V Postal survey 2006 7,997 77.1%  
OLIN IV+VI Postal survey, random 2008-10 15,001 80.0%  
OLIN VI Postal survey, random sample 2006 7,997   
OLIN IV+VI Clinical examination, random 2008-10 1,016 71.5% V 
WSAS Postal survey, random 2008 30,000 60.3%  
WSAS Clinical examination, random 2009-12 2,000 57.7% V 
OLIN IV Postal survey, follow-up 2016 6,083 ~80%  
OLIN VI Postal survey, follow-up 2016 5,281 ~76%  
OLIN VII Postal survey, random sample 2016 12,000** 58,3%  
*Case-control study, all participated. ** 245 deceased or not possible to trace. 
The participation rate of the clinical examination of cohort OLIN III in 
1994-95 was somewhat lower and the difference can be attributed to 
examination circumstances: the subjects were asked to come to the 
central hospital in Norrbotten while all other examinations were per-
formed at the local care centres in Norrbotten. 
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Questionnaires 
The OLIN short version postal questionnaire and the longer interview 
questionnaires were originally developed in 1984-1985 mainly from a 
revised version of the 1960 British Medical Research Council respi-
ratory questionnaire (Medical Research Council, 1965). The question-
naires were also influenced by the US National Heart, Lung and Blood 
Institute and the Tucson Studies questionnaires (Lebowitz et al., 1976). 
In 1992 and 1996 some questions about chest tightness and wheezing 
were added from the IUATLD questionnaire and the Swedish version of 
the ECRHS questionnaire (Burney et al., 1987; Björnsson et al., 1994). A 
question on dyspnea from the 1986 revised MRC questionnaire (Cotes, 
1987) was also added in the 1990s.  
The OLIN questionnaire has been used in studies in Nordic and Baltic 
countries (Pallasaho et al., 1999; Meren et al., 2001) and in Vietnam 
(Lam et al., 2011). Studies have been performed using the questionnaire 
in Sweden, Finland and Estonia under the FinEsS label (Pallasaho et al., 
1999; Meren et al., 2001; Lindström et al., 2001; Backman et al., 2014). 
The questionnaires include mainly questions about asthma, rhinitis, 
chronic obstructive pulmonary disease, chronic bronchitis, emphysema, 
use of asthma medication, dyspnea, respiratory symptoms, and nasal 
symptoms. Possible determinants of disease, such as family history of 
atopic and obstructive respiratory diseases, smoking status and occupa-
tion are also included. 
 
The questionnaires relating to this thesis have been used in all surveys of 
the OLIN cohorts among adults. The questionnaires have been described 
in detail previously (Lundbäck et al., 1991; Pallasaho et al., 1999; 
Rönmark EP, 2015). The short version of the questionnaire has also been 
validated against the GA(2)LEN questionnaire (Ekerljung et al., 2013). 
The core questions of the OLIN and WSAS questionnaires were close to 
identical. The short questionnaires have always been self-administrated 
by the subjects under study, while physicians, specially trained nurses 
and research assistants have performed the interviews. Data mainly 
collected by the interview version have been used in the papers of is 
thesis. The 2009 version is included in Appendices 1 and 2. 
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Clinical examinations 
At the visit clinical examination included measures of height, weight, and 
spirometry. Some studies of the OLIN project clinical examinations 
included skin-prick test, methacholine provocation, blood-samples, ECG, 
handgrip, six minutes walk test, oxymetry and, if indicated, arterial 
blood-gas sampling; these examinations were not included in the present 
thesis. 
Anthropometric values 
The date of birth was collected from the Swedish national registry. In the 
examinations in 1994-1995 of OLIN III, and in all examinations since 
2002, height was measured without shoes with 0.5 cm precision and 
weight with 0.5 kg precision with empty pockets and without jacket and 
shoes. At earlier examinations the participants were asked about height 
and weight. Self-reports of height and weight tend to underestimate 
weight and overestimate height (Gorber et al., 2007). Studies based on 
self-reports of height and weight may underestimate BMI. This does not 
affect identification of COPD, based on airflow limitation with the fixed 
ratio criterion. Since reference values include height it can influence the 
determination of the severity grade of the subject. 
Lung function testing 
Spirometry 
Lung function testing was performed on all subjects capable of blowing. 
Only expiratory capacities were performed. Dynamic spirometry 
included slow vital capacity (SVC), forced vital capacity (FVC) and the 
volume exhaled during the first second of a forced manoeuvre (FEV1). 
The procedures followed the ATS/ERS standards, except for the repeat-
ability criterion. In all OLIN the repeatability criterion for FEV1, SVC 
and FVC was ≤5% instead of ≤150ml deviation from the second highest 
value, or <100 ml difference if the spirometric values were <2 litres. In 
the WSAS study the goal has in addition a difference of <150 ml for the 
two highest values FEV1, SVC and FVC, except for values <2 litres, 
where the OLIN criterion was applied. Spirometry was considered as 
adequate when it successfully followed the recommendations. When the 
repeatability criterion was not fulfilled, trained professionals assessed the 
flow-volume curves, either at the time of examination or during the 
subsequent data management process. Reversibility testing was 
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performed 15 minutes after distribution of 0.4 mg salbutamol powder via 
discus in subjects with FEV1 <90% of reference values or a ratio of 
FEV1/VC<0.7 in 1994, and in all subjects in the 2009-2012 surveys. In 
the WSAS study bronchodilation was performed with a combination of 
0.4 mg salbutamol and 80 µg ipratropium bromide aerosols via spacer in 
all subjects. Trained personnel performed spirometries, which is of great 
importance since lung function testing depends on the individual’s 
cooperation  
Spirometers 
In all OLIN studies, a dry volume spirometer, the Dutch Mijnhardt 
Vicatest 5, was used until 2008 (paper I-IV). The Vicatest has been 
evaluated and regarded accurate (Weaver et al., 1981). From 2008 
Jaegers pneumotachometer has been used in the OLIN studies and in the 
WSAS study. This is a flow-sensing device, which calculates flow and 
volumes based on pressure measurement over a membrane (Jaeger, JLAB 
version 5.21 software, CareFusion, Würzburg, Germany). The spirometer 
complies with the ATS standards (Jaeger, 2016). At examinations daily 
calibrations were performed. 
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Results 
Incidence of COPD and risk factors based on inci-
dence 
Incidence 
Our study on incidence of COPD with 
the fixed ratio criterion and incidence 
of COPD GOLD grade 2-4 (paper I) 
was based on 1,237 subjects in 1996 
of whom 1,009 also participated 7 
years later. We could include 963 sub-
jects based on adequate spirometries 
in both 1996 and 2003. Point preva-
lence of COPD with the fixed ratio 
was 14.1%, who thus were excluded 
from the population at risk for 
developing COPD during the follow-
up period. The point prevalence of 
COPD grade 2 to 4 (further named 
“GOLD II-IV”) was 4.7% thus leaving 
a population at risk for GOLD II-IV of 
918 subjects. Subjects attending the 
first visit but not the second had 
significantly lower lung function even 
when prevalent cases of COPD in 
1996 were excluded. Thus the inci-
dence could be underestimated to 
some degree as low lung function, 
measured as FEV1 has been seen as a 
risk for further decrease. 
Cumulative incidence of COPD during seven years was 11.0% for COPD 
according to the fixed ratio and 4.9% for COPD grade 2-4. Calculated 
incidence rate of COPD was 16 cases/1,000/person/year and 7 
cases/1,000/year for GOLD II-IV. The cumulative incidence of COPD 
GOLD II-IV over the sever year-period was about six times greater 
among smokers (10.8%) than to non- smokers (1.6%). 
Figur 10. Flow chart of the cohort of paper I. 
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Risk factors for COPD 
Although more women than men developed COPD and COPD GOLD II-
IV, this was not significant, and in the adjusted analyses ORs were 0.66 
and 0.64 respectively. Thus we could not establish a difference in risk 
due to sex. Higher age at entry was significant for COPD grade 1 to 4 and 
smoking even for GOLD II-IV. All reported respiratory symptoms such 
as cough, sputum, chronic productive cough, recurrent wheeze and 
dyspnoea preceded COPD GOLD II, and this was true for incident COPD 
grade 1-4 except for cough.  Airways symptoms were frequently reported 
in the study sample but about twice as common among incident cases of 
COPD, compared to non-COPD. Cough was found to be the weakest 
symptom indicating future COPD. 
Prognosis 
Based on reports of respiratory symptoms 
in the postal questionnaire in 1985-86 and 
a random selection of individuals with no 
reports of respiratory symptoms, a sample 
of 1,655 individuals was invited for clini-
cal examinations in 1986, 1,505 partici-
pated. This sample was re-examined in 
1996-97, in 2002-2003, and followed up 
to 2006. Based on spirometry performed 
in 1986, 266 individuals were identified as 
having chronic obstruction with a patho-
logical ratio of FEV1/VC <0.70. Informa-
tion on mortality was collected until 2006. 
These subjects constitute the study sample 
for the study on prognosis of COPD 
(paper II). 
The overall prognosis for survival during 
20 years in the study sample was 46%. 
This shows a better prognosis of COPD 
than most studies based on patients from 
hospitals or health care. Even inthe oldest 
age-group reaching 86-87 years, by the end of the 20 years of follow up, 
25% were alive. 
Figure 11. Flow chart of the cohort of 
paper II. 
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Risk factors for death 
A somewhat higher proportion of women were alive at study end and 
men had significant higher risk for death in the regression model (H.R. 
1.51; 95% CI 1.02-2-23). Smoking habits were analysed. Although non-
smokers had the highest proportion of survivors, initial smoking habits 
were not risk factors for death in the regression model. There might be 
several reasons for this finding: quitters in 1986 might represent subjects 
with more advanced COPD or other cardiovascular disease leading to 
stop smoking; since the analyses did not include data on smoking habits 
after 1986, a large proportion of current smokers in 1986 might have 
become quitters. 
Higher grades of COPD according to GOLD were clearly associated with 
an elevated risk of dying, as was level of lung function estimated as FEV1 
of reference values. In bi-variate analysis, manual workers in industry 
had a higher risk for death compared to other socioeconomic class. This 
can reflect several risk factors such as smoking, low education, economic 
burden, and life-style. In the adjusted analysis the association with 
socioeconomic class disappeared. Subjects reporting chronic bronchitis at 
study entry, that is productive cough during at least three months during 
the last two years, had worse prognosis than subjects not reporting 
chronic bronchitis. 
Report of heart disease in 1986, i.e. myocardial infarction, heart failure, 
and any heart disease, was associated with higher risk of death but when 
adjusting for other factors only myocardial infarction remained sig-
nificant. Respiratory symptoms such as productive cough and dyspnoea, 
but not wheeze, were associated with worse prognosis. 
Markers for better prognosis 
Subjects with either report of asthma, with a positive reversibility test 
(increase >15% in FEV1 from baseline), or with hyper-reactivity to 
methacholine, were included in the study sample based on a pathological 
FEV1/VC ratio below 0.70. These subjects had the best prognosis. This 
was also found in subjects with atopy, defined as rhinitis. 
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COPD and heart diseases 
In 1994-95 a random sample, from the general 
population of Norrbotten, was selected for a study 
on COPD, restrictive spirometry and heart disease 
(paper III). The aim was to explore the association 
of heart diseases and hypertension with COPD and 
with restrictive lung function impairment. Conse-
quently the study could analyse subjects with low 
lung function, both as COPD and as restriction, 
with normal lung function as control group with 
respect to associations with ischemic heart disease 
and hypertension. 
We found high prevalence of ischemic heart 
disease, hypertension or medication for heart 
disease and hypertension in COPD grade 2 to 4, 
compared to normal lung function. Almost 60% of 
the subjects with COPD grade 3 and 4 had any of these cardio-vascular 
diseases The prevalence of these diseases in restrictive spirometry was 
similar as in COPD grade 3 and 4, also almost 60%. The prevalence of 
COPD and of restrictive lung function among subjects reporting heart 
diseases, hypertension and mediation was also significantly higher than 
among those not having these cardio-vascular diseases. Among subjects 
reporting heart failure and arrhythmia we did not find an association with 
COPD. 
In the adjusted analyses risk factor patterns, or associations, were quite 
different for COPD, restrictive lung function, and ischemic heart disease. 
The single shared significant association was age. Smoking and family 
history of obstructive lung disease were associated with COPD. Although 
smoking is an established risk factor for coronary heart disease we could 
not significantly ascertain this association. 
Intriguing associations remained between COPD and ischemic heart 
disease, and vice versa, in the adjusted analyses. These significant 
associations could be interpreted as causal inference although alternative 
explanations, such as common pathways and common exposures not 
included in our study, are more plausible. 
Figure 12. Flow chart of 
the cohort of paper III. 
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In the period 2009 to 2014 (paper V) two studies based on the general 
population were performed, one in Västra Götaland and the other in 
Norrbotten. We used the pooled sample from these two cohorts, and the 
study sample represents random samples in the same age span of the two 
areas. As a comparison we used a previous study (paper III). 
Figure 13. Flow chart of the cohort of paper V. 
Compared to the study in 1994 (paper III), prevalence of current smoking 
was lower in Norrbotten, 26.5% versus 15.1 %, and even lower in Västra 
Götaland, 11.4%. The mean age span in the latter study included some 
younger and older subjects compared to the study in 1994. The 
prevalence of COPD was lower in 2009 to 2014 and especially more 
severe disease was less prevalent. The pattern of association of COPD 
and comorbid heart diseases and hypertension was similar with some 
exceptions. In the study of 1994 (paper III) ischemic heart disease, i.e. 
angina pectoris, myocardial infarction and coronary intervention, was 
significantly associated with COPD, an association that remained after 
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adjusting for confounders. This association was found in the study of 
2009 to 2014 but was not significant in the adjusted model. In the earlier 
study we found no association between COPD and heart failure or 
intermittent claudication. The opposite was found in the latter study and 
heart failure remained after adjusting for confounders. 
COPD and BMI 
In the study (paper IV) our hypothesis was that both underweight and 
obesity were associated with COPD. Since our study sample was from 
the general population, the null-hypothesis would be that distribution of 
BMI among subjects with COPD is similar to subjects with normal lung 
function. 
Figure 14. Flow chart of the cohorts used in paper V. 
The study sample consisted of pooled data from several cohorts 
examined in 2002-2004 with a study sample of 3,942 subjects from the 
general population. Subjects with a restrictive spirometry were not 
included in the analyses. We used the BMI cut-off of 20 for denoting 
underweight for two reasons: that is the most common in the western 
world, and we had few subjects in the study sample with BMI<18.5. 
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Factors associated with high BMI, were male sex, former smokers, 
wheeze and dyspnoea, rural living, most heart diseases except for 
arrhythmia, diabetes, hypertension, and all socioeconomic groups 
compared to professionals and executives. Subjects reporting asthma had 
higher BMI while the COPD group had lower BMI, compared to subjects 
without asthma and COPD, respectively. 
FEV1, in percent of reference value, was not associated with BMI in 
subjects with normal lung function and among subjects with COPD grade 
1 and 2. In the more severe grades we found a correlation between BMI 
and FEV1: the more airflow limitation, the lower BMI. There were also 
associations of the ratio FEV1/VC versus BMI grades in the COPD group 
where the correlation showed a higher ratio with higher BMI grades. 
Compared to subjects with normal spirometry we found significantly 
higher prevalence of underweight in severe COPD, i.e. GOLD grades 3 
and 4. Regarding the other BMI grades in COPD there was no significant 
difference in prevalence versus the normal population except that COPD 
grade 2 had lower prevalence of pre-obesity and obesity. The association 
remained significant in the adjusted analysis. 
As in previous studies our study supports the association of underweight 
and COPD. We found no support from our data of an association 
between COPD and obesity. The prevalence of obesity inclined from 
COPD grade 1 to grade 3 and 4 where it was similar to prevalence in 
normal lung function. There are no known physiological reasons for an 
association between COPD and obesity other than that subjects with 
COPD can be less active and immobilised, thus gaining weight. Obesity 
does not affect lung tissues since fat does not deposit in the lungs. 
The distribution of BMI grades reflects the distribution in the normal 
population except that underweight is overrepresented in COPD severity 
grade 3 and 4. There is a strong case that underweight is caused by the 
disease. A reversed causation is not plausible in other aspects than that 
muscle weakness can produce low forced expiratory capacities. Since the 
study used forced capacities both for FEV1 and VC, such a bias would be 
minimised. 
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Discussion  
Discussion on methodology 
Bias 
The possibility or presence of bias should be considered and taken into 
account in all studies. Although it is stated: “Bias in studies should not 
happen” (Dawson et al., 2001, p. 306), this is seldom the case and not 
always desirable to avoid (Rothman et al., 2013). Bias is contextual and 
dependent on the research question. Bias can skew the data in several 
ways such as in selection, procedures, and measurements. 
 
In the present studies, based on samples randomly selected (paper III and 
IV) or stratified based on birth year (paper I and II), or a combination 
(paper IV), control groups are included. Since it was likely that the cases, 
for example subjects with COPD, differed from the subjects in the 
control group, in other ways than just the disease, adjusted analyses, by 
means of binary multivariate logistic regression and Poisson regression 
methods, were performed. This approach has the dual intent to adjust for 
confounders and to identify associations that can represent risk factors.  
Selection bias 
When the purpose is to define prevalence, changes in prevalence or 
incidence in the population the study sample should be representative of 
the study base. In some studies (paper II and IV) selection of subjects is 
in part based on report of symptoms. This can represent bias if 
conclusions are on prevalence of disease or symptoms. As our intention 
was to study associations this selection method is of less importance. The 
strength of association can be overestimated but the association is still 
valid. 
Non-responders and non-attendance can skew data somewhat. An 
intrinsic part of the problem with non-responders is the fact that analyses 
of non-response is limited, otherwise they would not be non-responders. 
High response rate limits the bias of non-responders and a high response 
rate will increase the power of the statistical analyses. 
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There is a growing concern for decreasing response rates in epidemi-
ological studies. Non-responders reduce the effective sample size and this 
can introduce bias. Average response rates to mail surveys published in 
medical journals have previously been about 62% (Asch et al., 1997), and 
are probably lower at present. 
The response rate in the present studies can be considered as high (table 
3). A previous study of non-responders to the postal questionnaire of 
Cohort I (Rönmark et al., 1999), with 85% response rate, found that 
young men, current smokers, and manual workers were over-represented 
among non-responders. Respiratory symptoms and asthma were more 
prevalent in the non-response group. A study from Norway, with a 
response rate of 89%, found only minor differences between responders 
and non-responders. A calculated higher response rate did not alter the 
incidence rates of the five respiratory symptoms and asthma or their 
associations to sex, age, and smoking habits (Eagan et al., 2002). In a 
study on the WSAS material (Rönmark et al., 2009) non-responders and 
late responders, were analysed. The initial response rate was initially 
33% rising to 62% when late responders were included. Analyses of late 
responders and non-responders revealed that increased participation rate 
did not alter the risk estimates. In this perspective response rates in the 
present studies can be assessed as adequate for the results. 
Measurement bias 
Measurement bias arises when measures do not reflect the outcome due 
to inappropriate methods. Measurements included in the present studies 
were lung function, anthropometric values, report of smoking habits, 
diseases, medication, educational level, and occupation etc. 
Values of length and height were collected by direct measurement since 
2002 and in the OLIN III cohort in 1994-1995. The studies on COPD 
comorbidities (paper III), on COPD and BMI (paper IV), and on COPD 
comorbidities in 2009-2014 (paper V), recorded height and weight by 
direct measure. In the study on incidence (paper I) the values were based 
on self-report. Height was recorded on the base of self-report, which can 
affect FEV1 of reference value since there may be an overestimation of 
height also in our study. This can skew the data some and attribute higher 
COPD grades to subjects, than would be the case when using direct 
measures. BMI was not included in the analyses in the study on 
incidence. In the study on prognosis in COPD (paper II) anthropometric 
values were based on self-report. This can have an effect on BMI levels, 
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and on severity grades of COPD, as in the study on incidence. BMI levels 
may have been underestimated and COPD severity grades somewhat 
overestimated. The fixed ratio criterion was applied in all studies, and 
direct measures of height in analyses with the LLN criterion, the 
identification of airflow limitation, consistent with COPD, were used. 
Method of collecting data on length did not infer bias in this respect. 
Measurements of lung function were performed by spirometers calibrated 
daily. A small random variation is acknowledged. In our studies we used 
strict criteria for labelling subjects as COPD, restrictive spirometric 
pattern and normal. It should be approved that the randomness in the 
measures has some impact for subjects just around the cut-off limit. 
There is also a day-to-day interindividual variation of expiratory 
volumes. This pertains to all epidemiological studies based on 
spirometry. The anthropometric measures are preformed similarly in all 
subjects. A measurement randomness, or imprecision, affects all 
measures, and should not affect our results in high degree. 
We have used the spirometric values for calculating the ratio of FEV1 and 
VC and, by this mean, identifying subjects with an airflow limitation 
consistent with COPD. In the first four studies (paper I-IV) we have used 
the fixed ratio with the highest values of FEV1 and SVC/FVC before and 
after bronchodilation. This gives the highest prevalence of COPD (Gove 
et al., 1987), due to high sensitivity of airflow obstruction (Chhabra, 
1998). The prevalent cases are used for identifying risk factors, 
prognosis, and comorbidities. The fixed ratio could identify older persons 
without disease, i.e. subjects without symptoms, limited exposure and a 
not compromised prognosis. This could give some “noise” to the “signal” 
(Silver, 2012) missing a significant association or lower the strength of 
association. We therefore, as tests of sensitivity, applied the LLN 
criterion (paper III and V), and the more strict criteria of the GOLD 
document, and of the ERS standard, that is, only post bronchodilator 
values as comparison (paper V). The patterns of associations remain 
similar but the strength of association varies somewhat. 
In paper III we excluded subjects with a restrictive spirometric pattern 
from the group with a normal FEV1/VC ratio, but included this group in 
the analyses. Subjects with low FVC but a normal ratio of FEV1/FVC do 
have low FEV1. In previous studies, based on one lung function variable, 
this group can have been included in the cases. In later studies, based on 
the FEV1/VC ratio, this group can have been included in the normal 
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group. Those with both low FEV1 and low VC share several 
characteristics with the COPD group but are divergent in other respects. 
Our methods adhere to guidelines. There is no scientific evidence that 
would guide in the choice of the fixed ratio or the lower limit of normal 
criterion. The measurement methods we have used gives answers 
accordingly. Based on sensitivity analyses we conclude that our methods 
are apposite and our results sound. 
Recall bias 
Information on smoking, airway symptoms, diagnosis of pulmonary and 
other diseases and medication was based on self-reports from subjects in 
the interview situation. Physicians’ diagnoses were not validated by 
patients’ charts, and smoking habits were not validated by for example 
blood testing of cotinine. With respect to reports on other diseases and 
medication we do not have reason to suspect a systematic bias between 
subjects with airflow limitation, smoking habits and normal lung 
function. Smoking habits have been seen to be underreported in other 
studies (Todd, 1978). This may be the case in our studies, which could 
lead to an underestimation of association between smoking and COPD, 
and smoking and heart disease. On the other hand, in our longitudinal 
studies reports of smoking habits are rather stable between follow-up 
investigations. Smokers might underestimate symptoms of airways. The 
mMRC scale, although coarse, can be regarded as a valid instrument 
levelling out differences between smokers and non-smokers in recall 
bias. 
In the present studies recall bias may underestimate smoking habits, 
which thus could yield somewhat lower strength of association, but we 
have no reason to suspect a systematic error making the findings invalid. 
Observational bias 
There are three aspects of observational bias: 1. Different persons 
preformed the interviews and the spirometries. 2. Selection of variables 
are decided on the basis of known and suspected associations and risk 
factors. 3. In a more philosophical aspect, every attempt to measure 
influences the measured object. This latter bias can be seen as present in 
all studies. 
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There is always some randomness in observations performed by the same 
observer and between observers that certainly is present in our studies. 
That this observational bias would infer a systematic error in the analyses 
of incidence, risk factors and comorbidities is unlikely since it can be 
assumed that observational bias is randomly distributed in the material. 
All studies are, or should be, based on a hypothesis. Forming a 
hypothesis builds on what is already known with research questions not 
answered. The most important research mission is to further push the 
boundaries of what we know. Selection of variables and building 
hypotheses is based on the pre-understanding of the researcher and this 
will change over time and should progress. Our studies has taken stand 
on what is presumed to be known but attempts to address areas where 
research results are conflicting or where research questions still are 
unanswered.  
Reliability and validity 
Reliability and validity are often seen separate but are certainly 
interconnected. Reliability concerns the quality of measure and every 
aspect of validity is dependent on the reliability of the study. In the 
present studies there are several measures that could be discussed with 
respect to reliability. The lung function testings are probably among the 
best in the world performed by well-trained and experienced staff. There 
are day-to-day variations of FEV1 and VC among normal subjects, and 
among COPD subjects but probably less in more severe grades (Albert et 
al., 2012). A systematic error in the spirometries is unlikely. 
Anthropometric measures are obtained similarly through out the studies 
and for all subjects and weight is based on measure and not self-report. 
The quality of the self-reports of diseases is dependent on several crucial 
steps: physicians diagnosis and how correct that is, clear information to 
the patient, the patient’s perception and remembrance, and the report in 
the interview situation. There is both underdiagnosis and misdiagnosis of 
COPD (Arne et al., 2010; Walters et al., 2011). In our study, airflow 
limitation consistent with COPD is obtained by spirometry, thus avoiding 
difficulties with self-reports. More acute diseases, such as myocardial 
infarction, and chronic diseases with long-term treatment, such as 
hypertension and diabetes, are more accurately reported (Okura et al., 
2004). As discussed in paper V heart failure reports may be more 
correctly reported in recent years. There are readily accessible diagnostic 
tests, such as brain natriuretic peptides, and increased utilisation of 
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echocardiography. A shift has occurred from diuretics and digoxin to 
more active treatment with beta-blockers, ACE-inhibitors, and aldoste-
rone antagonists. Various pacemaker devices,, such as implantable 
cardioverter defibrillator and cardiac resynchronization therapy (CRT), 
have come into use. It is plausible that information to patients have 
improved. The report of medication is based on meticulous inquiring, 
where subjects were asked to bring a list of their medication. Including 
data on medication thus gives a further strength to the report of diseases. 
Smoking habits are often underreported. In later studies the simple 
question on smoking has been amended with a careful assessment of 
smoking habits during life-time (paper V). This can be assumed to limit 
underreport of smoking habits. Data on diseases reflects the subjects’ 
perception of what disease they have. 
Thus there are imprecisions in the measures which may underestimate 
strength of associations but we have no reason to believe that this have 
affected the presence of associations in our studies. 
Validity 
Some of our studies are based on randomly selected subjects (paper I, II, 
III and V) while one study also contains some subjects initially selected 
on the basis of symptoms. The first three studies can be judged as 
reflecting the population of Norrbotten. In paper V we included a cohort 
from the southwest of Sweden together with a cohort from Norrbotten.  
Internal validity is dependent on minimizing systematic errors but should 
be judged with focus on the hypothesis.  In research, internal validity is 
the extent to which a causal conclusion based on a study is warranted, 
which is determined by the degree to which a study minimizes systematic 
error (or bias). It contrasts with external validity, the degree to which it is 
warranted to generalize results to other contexts. Internal validity here 
reflects the accuracy of results for the study individuals, or dependability 
of associations found within the study. The results suggest that the 
previous studies of the OLIN cohort are valid for the rest of Sweden, and 
probably for COPD worldwide. Both internal and external validity are 
high in our studies. 
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Discussion on main results 
Our studies are based on cohorts derived from the general population, 
and COPD is defined by lung function testing, thus giving the possibility 
to investigate risk factors, prognosis, and comorbid conditions without 
the bias of underdiagnosis of airflow limitation in COPD. 
There are two important aspects affecting research outcome in epidemi-
ological studies on COPD. As is seen in several studies before there is a 
great deal of underdiagnosis, and even misdiagnosis of COPD most often 
due to a low utilisation of lung function testing (Lindberg et al., 2006; 
Lindström et al., 2001; Mannino et al., 2000). Even some epidemiolo-
gical studies, especially earlier studies, on COPD did not include 
spirometry as a criterion (Chen et al., 2000; Ställberg et al., 2013). Many 
studies on prevalence, risk factors, comorbidities and prognosis are based 
on patients in primary or secondary care settings (Steuten, 2006). These 
studies are valuable and valid in these particular contexts. 
Incidence and risk factors for COPD  
We conclude that the 7-year cumulative incidence, with the fixed ratio 
criterion of GOLD, and with a more restricted criterion of grade 2 and 
higher, is 11.0% and 4.9%. Incidence rates were correspondingly 16 and 
7 cases/1,000/year. Incidence is of some interest by itself by giving an 
indication of how many new cases that could be in need of intervention 
in the health care system.  
Two older studies on incidence (Huhti et al., 1980; Krzyzanowski et al., 
1986) were not based on present criteria. Only few studies had been 
published with comparable criteria as of our study. Although based on a 
somewhat younger cohort, a report from the Copenhagen City Heart 
Study yielded an incidence rate of COPD of 19 and 9 cases/1,000/year 
based on 5 and 15 years cumulative incidence. In a symptomatic cohort 
of the OLIN studies (Lindberg et al, 2005) the incidence rate of COPD 
can be calculated to 14 cases/1,000/year, based on a 10-year follow-up. A 
report from Bergen (Johannessen et al., 2005), with a follow up time of 9 
years, reported an incidence rate of 7 cases/1,000year, in a younger 
cohort than ours. In 2006 a 25-year follow-up study, also from 
Copenhagen (Løkke et al., 2006), reported incidence of COPD that can 
be estimated to 17 cases/1,000/years. A few years thereafter, the 
incidence of COPD in young and middle-aged cohort within the ECRHS, 
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with a median follow up of 8.9 years, was estimated to 2.8/1000 persons 
per year (de Marco et al., 2007). It is obvious that level of incidence is 
dependent on the study base, the study sample, and level of exposure, 
foremost the prevalence of current smoking in the population. 
Incidence studies can avoid the risk of reverse causation, i.e., identifying 
a consequence of the disease as a risk factor. We found smoking carrying 
the highest risk for COPD, and ex-smoking also for GOLD II, that is 
more severe disease. Higher age was a risk factor for COPD, but the 
highest age was not a risk factor for GOLD II. We could not establish 
that any of the sexes had significantly higher risk for COPD. Smoking 
and age as risk factor for future COPD were identified in all studies 
referred to above.  Sex as a risk factor was only found in the Danish 
study (Vestbo et al., 2002). 
We found respiratory symptoms associated with future COPD. This was 
the finding in the incidence studies analysing respiratory symptoms 
(Johannessen et al., 2005; de Marco et al, 2007) except in the Danish 
study (Vestbo et al., 2002). We have interpreted our finding as an early 
sign of future COPD due to a common exposure leading to both 
respiratory symptoms and COPD. There may be a host factor not yet 
identified. 
Age as a risk factor for COPD is more complex. There is strong support 
that COPD develops after years of unhealthy exposure. COPD is 
uncommon in age before middle-age. The assumption is that COPD is 
caused by exposure, where several have been identified, although not all. 
Age and exposure time co-vary. Thus, adjusting for age or operating with 
criteria that minimise the effect of age might yield an overadjusted 
analysis.  
In incidence studies the study population consists of nondiseased with 
respect to the disease, the population “at-risk”1 of developing disease. 
The distinguishing of these subjects is dependent on the criteria for 
identifying subjects with the disease, since these are excluded from the 
study group. If the time span is prolonged between the investigations 
there is a possibility that subjects developing the disease and rapidly 
               
1 ”At risk” in this context represents the whole “un-diseased” (with respect to the 
disease in focus) population, in contrast to GOLD stage 0 where “at risk” 
denotes subjects without COPD but with symptoms of airway disease. 
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decline do not attend at the follow up. This can be seen as a minor 
problem with respect to COPD as it develops slowly in most cases. There 
is some support that individuals with low lung function from birth, due to 
various premature factors, can have a pathological FEV1/VC ratio 
(Alonso-Gonzalez, et al., 2013). These subjects can be exposed to factors 
leading to COPD but are not included in the population at risk in 
incidence studies being, by definition, not part of the population at risk.  
With the incidence study more solid conclusions can be drawn with 
respect to risk factors for COPD. Current smoking is a clear risk factor in 
our study, while ex-smoking is prominent in cross-sectional studies, 
especially in more severe COPD, where subjects have stopped smoking 
due to the disease. Smoking is thus the far most prominent risk factor for 
COPD. 
Our study confirms smoking and age as important risk factors. It can be 
noted that former smoking had an O.R. of 1.71 and non-significant for 
the fixed ratio, but highly significant with an O.R. of 5 for COPD grade 
2-4. This finding could reflect that some subjects continue to lose lung 
function despite quitting smoking (Fletcher 1976). Age, as a risk factor, 
can represent several aspects: since COPD is considered as caused by 
exposure during an extended time, age can thus indicate various 
exposures; decline in lung function is seen as part of normal ageing and 
since the decline in FEV1 and VC are of similar magnitude, the ratio 
FEV1/VC diminishes accordingly. 
There is a clear linkage between incidence and prevalence. Prevalence 
could be described as the sum of inflow (incidence) and out-flow (either 
remission or death). In our cross-sectional studies (paper III, IV and V), 
the same associations were found, i.e. age and smoking. Both prevalence 
and disease severity were lower in the cohort with low prevalence of 
smoking (paper V) compared to the cohort with higher smoking 
prevalence (paper III).  
In our study we used two criteria for COPD: a fixed ratio of the GOLD 
criterion and more severe disease with FEV1 of less than 80% of 
reference values, which is equivalent to older BTS guidelines. Smoking 
remained as a risk factor preceding COPD with both criteria. Smoking 
precedes COPD and a reverse causation is therefore excluded, and 
certainly not plausible. 
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In the incidence study socioeconomic group was not significantly asso-
ciated with incident COPD. In our cross-sectional studies socioeconomic 
status is associated with COPD but the strength of association did not 
stand in the adjusted analyses (paper III and IV). Socioeconomic group is 
a broad and indistinct variable for exposure, which can represent level of 
income, educational level, exposure at work and at home, food intake, 
physical activity and other. The most obvious association is with 
smoking habits. It might be that the difference of important exposure 
factors do not differ that much in the general population in Sweden of our 
studies.  
Prognosis and COPD 
In our study on prognosis of COPD subjects with COPD, defined by an 
airflow limitation with the fixed ratio criterion, were followed for 20 
years or to death. Prognosis of chronic diseases, such as COPD, is depen-
dent on included cases and disease severity at inclusion. Our study in-
cluded all COPD severity grades, whereof 36% in grade I, i.e. mild 
disease, and sometimes seen as of minor clinical relevance. The risk of 
death in this group was as high as 20% in the group aged 50-51 at entry. 
An important finding is that asthma phenotype of COPD, viz. subjects 
with some reversibility or concomitant asthma, but with persistent 
airflow limitation, revealed good prognosis and that subjects with chronic 
bronchitis phenotype had worse. Considering reversibility in spirometry 
might be of importance, contrary to the recommendations of several 
guidelines. 
We did not collect cause of death, which can be seen as a limitation. 
However, the Swedish death certificates are of somewhat limited value 
since only about 10% are based on autopsies and for lung diseases as low 
as around 5% (Socialstyrelsen, 2013). The quality of death certificates 
could be as low as 50% with incorrect causes of death (Johansson et al., 
2000). 
Prognosis of a disease is of major interest although the prognosis for the 
individual patient often is hard to determine. COPD is, in our study, 
associated with a better prognosis than could be expected. Quitting 
smoking is the preeminent way to minimise the progression. Although 
not significant in our study, the efforts to prevent smoking and to support 
quitting are supported. 
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COPD and heart disease 
Our studies verify and illustrate the presence of heart diseases, 
hypertension and medication for these diseases in accordance with most 
other studies. Especially ischemic heart disease (paper III) and heart 
failure (paper V) were significantly associated with COPD. 
Smoking rates has been used to estimate the prevalence of COPD in the 
general population (Stang et al., 2000). With fifteen years apart 
prevalence of smoking was halved in our study areas and we found a 
lower prevalence of COPD but not of heart disease and hypertension 
comorbidities. COPD is a disease where smoking has high impact while 
risk factor pattern for heart diseases is more multifaceted. Although 
smoking is an established risk factor for coronary heart disease 
(Jousilahti et al., 1999; Khot et al., 2003), we could not significantly 
ascertain this association; risk factors for ischemic heart disease are 
multifactorial and complex with risk factors not included in our studies. 
It is shown that COPD is associated with several comorbidities such as 
depression, anxiety disorders, osteoporosis, diabetes, hypertension, car-
diovascular diseases, and TIA/stroke (Curkendall et al., 2005, Mannino et 
al., 2008). Many previous studies have been performed with older crite-
ria, than current, or based on clinical diagnosis, or lack comparisons with 
subjects without COPD. 
The overall finding of the two studies (paper III and IV) strengthens the 
conclusion that the co-existence of COPD and heart diseases and hyper-
tension is present and important to recognize (Figure XX.). 
COPD and heart disease share common risk factors such as smoking, 
work exposure and life style aspects. Smoking is solidly associated with 
development of COPD and a risk factor for ischemic heart disease 
although heart disease risk factor pattern is more complex. 
Current smoking has diminished in Sweden since middle of the 1980th 
(Folkhälsomyndigheten, 2016). In the present study (paper V) the aim 
was to analyse prevalence of COPD and associations with, or risk factors 
for, COPD in two distinct geographical areas of Sweden. We used a 
pooled sample from the OLIN studies in Norrbotten with a sample from 
the WSAS study in Västra Götaland. The sample represents random 
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samples in the same age span of the two areas. As a comparison we used 
a previous study (paper III). 
Figure 15. Comparison of prevaelnce of smoking, COPD and comorbidities in COPD in 
1994 and 2009-2014, adapted from paper III and V. 
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When comparing prevalence of smoking and of COPD in 1994 (paper 
III) and 2009-2012 (paper V) there seems to be correlation. Low preva-
lence of current smoking is associated with a lower prevalence of COPD 
(Backman, Eriksson et al., 2016b). The association between COPD and 
heart diseases was not altered by lower smoking habits. 
Socioeconomic status is in our study based on report of work based on 
SEI codes (Statistics Sweden, 1982) and our division in 5 groups can 
represent several exposures such as work exposure, income, living area, 
education and life-style. Socioeconomic classes revealed clear asso-
ciations with ischemic heart disease but not for COPD nor for restrictive 
lung function. 
Comorbidity can be due to common risk factors and common biological 
pathways but there are possibilities that one disease induces another. Few 
diseases come alone and many have multiple illnesses. Most ailments 
come with age and share common risk factors. Awareness of comor-
bidity, and even multimorbidity, probability and likelihood of such con-
ditions is of great importance for the clinicians with respect to further 
investigation and treatment. 
COPD and BMI 
Underweight, i.e. low BMI, in COPD has been verified earlier and is 
most probable a consequence of COPD. We found underweight only in 
COPD grade ≥3. High prevalence of obesity in COPD has been seen in 
some studies. Adipose tissue plays an active role in immunological 
organs that secrete protein mediators, adipokines (Exley et al., 2014). The 
two best characterized adipokines are leptin and adiponectin and they 
play a role in impaired lung function including asthma (Newson et al., 
2013). Leptin is correlated with increased BMI and induced inflam-
mation, while adiponectin is decreased in obese patients, but can be 
elevated in COPD (Chan et al., 2010), and has an anti-inflammatory role. 
The balance between those two adipokines can modulate the systemic 
inflammation. Thus, obesity or underweight could indirectly modulate 
the COPD-induced systemic inflammation and the corresponding comor-
bidities, affecting the prognosis and the overall mortality. 
Our studies did not reveal a higher prevalence of obesity compared to 
subjects with normal lung function, neither could we show an association 
with diabetes. Obesity and diabetes correspond. The findings in other 
studies might reflect the situation in that particular context, i.e. society. 
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Underweight and weight loss is associated with COPD and worse 
prognosis (Hallin et al., 2007; Lainscak et al., 2011) but the reverse 
seems to be the case with coronary artery disease (Flegal et al., 2007). 
Smoking is associated with low BMI, whereas ex-smoking with high 
BMI. Smoking and nicotine could reduce weight by different mechanism 
as appetite decrease and inducing energy expenditure (Chiolero et al., 
2008). Smoking cessation has been associated with weight gain (Bush et 
al., 2016). In a recent study it was found that quitters gained 2.6 kg more 
over 5 years compared to continuing smokers (Tian et al., 2015). Thus 
the pattern of association is complex. 
In a very recent study (The Global BMI Mortality Collaboration, 2016), 
based on more than 10.5 million participants, concludes that under-
weight, pre-obesity and obesity are all associated with a higher risk for 
death than normal BMI. This association was also present in respiratory 
disorders, but the best prognosis regarding respiratory diseases was found 
around 25, i.e. both under and slightly over 25. BMI in the range of pre-
obesity had just slightly higher risk. 
The association of underweight and COPD can be due to several aspects; 
COPD and underweight share the common risk factor of smoking, COPD 
in advanced grades can lead to underweight and the causes of this are 
discussed – malnutrition due to increased dyspnoea with ventricular fill-
ing, high energy expenditure and presence of cachectic mediators. 
Muscle weakness can generate a lower expiratory flow as measured with 
FEV1 but with preserved vital capacity. 
There are conflicting results and views of COPD and obesity. Some 
studies indicate high prevalence of obesity among subjects with COPD 
(Steuten et al, 2006, Eisner et al., 2007), and a review article also con-
cludes that there might be a high prevalence of obesity in COPD 
(Franssen et al., 2008). The relationship between COPD and obesity is 
uncertain. COPD could lead to obesity due to limited physical activity 
with preserved energy intake. COPD and obesity can have the same life 
style factors. Adipose tissue assembles in the abdomen, the buttocks and 
in the extremities but not in the lungs. Adiposity would does not lead to 
narrowed airways. 
Prevalence is dependent on incidence, remission and life expectancy. 
Incidence of COPD among subjects with obesity might be lower due to 
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our definition of COPD. Vital capacity is lower in obese subjects and that 
interfere with the FEV1/VC ratio. Remission might occur due to the same 
fact, in case vital capacity lowers. It has been suggested that overweight 
and obesity can lead to underdiagnosis of COPD (Sahebjami et al., 1996, 
Çolak et al., 2015) since FVC is more affected than FEV1 in subjects 
with high BMI. Life expectancy is shorter in subjects with obesity 
compared to subjects with normal weight and even underweight, except 
for cachexia. Thus there are many aspects to take into account in studies 
of lung function impairment and obesity, and lots of known unknowns, 
and unknown unknowns. 
There are varying criteria for COPD and reference values differ. We have 
used the fixed criterion in most studies. The value of this decision limit is 
debated. For sensitivity testing we applied the LLN-criterion based on 
our own reference values and on the GLI reference values, and we also 
applied two other reference values on the study sample (paper IV). Since 
we excluded subjects from the analyses who had a restrictive pattern on 
spirometry based on FVC< 80% of various reference values, this 
influenced the size of the group with normal spirometry and the COPD 
group as well. With some variation the sensitivity analyses yielded 
similar associations of BMI grades and COPD. 
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Ethical considerations 
Performing epidemiological studies raises some ethical issues. All the 
studies of the OLIN project and the WSAS study are, of course, con-
firmed by ethical committees. From within the OLIN studies 50.000 sub-
jects were engaged in the present research project, and all participated 
voluntarily without recoupment. The same was the case in the WSAS 
study. The following ethical aspects can be identified: 
Benefits compared to the cost for the research projects 
All OLIN co-workers have performed large amount of dedicated work, 
some travelling and spending nights away from home. The OLIN and 
WSAS studies have resulted in several doctoral thesis and PhD degrees 
with individually achieved research competence. Furthermore a large 
amount of research articles, conference papers and more popular science 
articles. It can also be regarded as an obligation to use as much data as 
possible for analyses and publication since so many voluntarily have 
contributed with time, measures of lung function and other, answering 
questions. 
Benefits and costs for the study subjects 
The contribution of every subject has been seen as important and has 
been done without economic substitution. The present author, as several 
other participants in the studies, has had the opportunity to share our 
findings in several patients’ organisations without grants.  
Findings suggesting pathology or disease 
The studies include lung function testing, measuring blood pressure, 
oxygen saturation and ECG. Pathological findings have been assessed by 
any of our physicians in the studyteam, and the individual has been 
referred to health care for consulting, when judged as needed. The author 
was engaged in the OLIN studies that way. An individual with a clearly 
pathological spirometry as of COPD was referred to my clinic, included 
in a COPD rehabilitation program, and was prescribed appropriate 
medication. 
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Findings of risk factors and unhealthy habits 
The foremost unhealthy habit is current smoking. We have included 
questions on smoking habits in our studies. When a subject reported 
current smoking we included measurement of dependency and the 
individual has, with respect and integrity, been advised to quit smoking. 
Information on smoking cessation programs was been given and where to 
find these. No further advice were given with respect to healthy and un-
healthy habits.. 
Gender aspects 
The studies include subjects of both sexes and all are subject of the same 
investigations. Selection of subjects were preformed without respect to 
sex. 
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Conclusions 
Incidence of COPD was found to be 11.0% during 7 years according to 
the fixed ratio criterion. For moderate to very severe COPD it was 4.9%. 
Risk factors for subsequent COPD were age and smoking habits. Report 
of respiratory symptoms at study entry was associated with succeeding 
COPD and could be regarded as early signs of the disease. We did not 
find gender or family history of obstructive lung disease to be risk factors 
for later COPD. 
After 20 years follow up of subjects with COPD, identified by the fixed 
ratio criterion, 54% had died but prognosis was found to be better than 
formerly reported. Among subjects with very severe disease at entry the 
20-year survival was as high as 19%. Death was related to age, male sex, 
disease severity, concomitant ischemic heart disease and heart failure at 
entry. Low lung function, measured as FEV1 of reference value, was 
associated with death and survivors kept their lung function stable. 
Subjects reporting rhinitis, asthma, or showed bronchial variability, had 
the best prognosis while subjects reporting chronic bronchitis had worse 
prognosis. 
We found a high prevalence of heart disease and hypertension among 
subjects with COPD, most pronounced in more severe disease. Also 
among subjects with report of heart diseases we found a high prevalence 
of COPD. 
In the study on comorbidity in COPD with lower prevalence of current 
smoking, performed about 15 years later than the abover referred study, 
we found lower prevalence of COPD but the pattern of association of 
heart diseases and hypertension with COPD was similar. 
We found BMI to be lower in subjects with COPD, than among subjects 
wit normal spirometry. Underweight, defined as BMI<20, was found 
only in severe disease. Contrary to previous suggestions we could not 
establish that obesity is associated with COPD. 
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Future perspectives 
Epidemiological studies on COPD have several unanswered issues.. 
Major risk factors for COPD have been identified. In a context with low 
smoking prevalence, COPD might still be prevalent. Risk factors, other 
than current, past or passive smoking, are still to be identified. No single 
risk factor or all together can count as a full explanation. There is still a 
randomness to be investigated further. 
Another issue to be addressed is the finding of low lung function but with 
a normal ratio of FEV1/VC. The value of dynamic spirometry in 
identifying a restrictive pattern is still to be explored by science. 
Research results in this area can be of great importance in the clinic. 
At the present there are somewhat divergent views on the decision limit 
for the airflow limitation of COPD. There is no scientific evidence 
supporting the two major conflicting views: the fixed ratio and LLN. 
There is a need of longitudinal studies, foremost with respect to 
prognosis and treatment outcome.  
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Appendices 
Appendix 1 
The Swedish version of the OLIN questionnaire for structured interviews 
from 2009  
Appendix 2 
The English version of the OLIN questionnaire for structured interviews 
from 2009  

Appendix 1 
 
 1 
 
Vuxna intervjuformulär OLIN (2009) 
 
 
 Undersökningsdatum:     år________mån__________dag__________ 
 
 Intervjuare  ______________________________________________ 
 
 
 
Personuppgifter 
 
1. Namn  __________________________________________________ 
 
Adress __________________________________________________ 
 
Telefonnummer hem _____________________________________ 
 
  arbetet _____________________________________ 
 
 
2.  Pnr  ________________________________________________ 
 
 
3. Etnisk tillhörighet 
 Kaukasier  (  ) 
 Afrikan (  ) 
 Asiat/oriental (  ) 
 Annan (  ) 
 
4. Kön 
 Man (  ) 
 Kvinna (  )  
 
       
 
5. Tätortsgradient ___ 
 
 
 
 
Undertecknad medger att blodprov tas och sparas för analys av allergi-antikroppar 
och andra allergi eller astma/KOL relaterade analyser inklusive genetiska markörer.  
Prover registreras vid Bio-banken, NLL.   
 
 
………………………………………………………      
Signatur 
 
Appendix 1 
 
 2 
Hosta och expektorat 
 
6. Har Du haft långvarig hosta under det senaste året (12 månaderna)? Nej (  ) 
  Ja (  ) 
 
7. Brukar Du hosta eller harkla Dig på morgonen? Nej (  ) 
  Ja (  ) 
 
8. Brukar Du hosta eller harkla Dig under andra tider på dygnet? Nej (  ) 
  Ja (  ) 
 
9. Brukar Du hosta eller harkla upp slem från bröstet, eller känner Du             Nej (  ) 
    att det sitter slem i bröstet som Du har svårt att hosta eller harkla upp?            Ja          (  ) 
 
10. Hostar eller harklar Du upp slem (eller har slem som det är svårt att             Nej        (  ) 
   få upp trots hosta) de flesta dagar i perioder om minst 3 månader per år?              Ja         (  ) 
 
Om  ja,  
 
11.    Sedan hur många år? Antal år      ____ 
 
  
 
Pip i bröstet eller väsande andning 
 
12. Brukar Du ha pip eller väser det i bröstet då Du andas?               Nej (  ) 
                Ja (  ) 
 
13. Har Du någonsin, nu eller tidigare, vid något tillfälle haft pip eller  Nej (  ) 
        väsningar i bröstet då Du andas? Ja (  ) 
 
14. Har Du haft pip eller har det väst i bröstet vid något tillfälle under  Nej (  ) 
        de senaste 12 månaderna? Ja (  )  
 
Om Ja på 14, besvara 15-17  
 
15. Har Du varit det minsta andfådd när Du haft pip eller väsningar i bröstet? Nej (  ) 
                                                                                                                           Ja (  ) 
 
16. Har Du haft detta pip eller väsande i bröstet utan att samtidigt                              Nej (  ) 
      vara förkyld? Ja (  ) 
 
17. Har Du pip i bröstet eller väsande andning de flesta                                Nej   (  ) 
      dagarna i veckan?                                                                                     Ja, periodvis (  ) 
   Ja (  ) 
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Andnöd 
 
18.    Är Du rörelsehindrad (av andra skäl än ev. hjärt- Nej/ej rel (  ) 
         eller lungbesvär)? Ja (  ) 
 
Om Ja,  
 
19.    Av vilka skäl? Cerebrovaskulär sjukdom (  ) 
  Muskelsjukdom (  ) 
  Rörelseinskränkning i extrem. (  ) 
  Övrigt:___________________ (  ) 
  Rullstolsburen (  ) 
   
     
20. Har Du någonsin besvär med din andning? Nej (  ) 
  Ja (  ) 
Om Ja,   
 
21. Har Du dessa besvär För jämnan så att andningen aldrig är riktigt bra (  ) 
  Återkommande men avlösta av besvärsfria perioder (  ) 
  Endast vid enstaka tillfällen (  ) 
 
 
22. Anfåddhet vid ansträngning - MRC dyspne skala   
 
Vilket påstående stämmer bäst överens med dig? 
 
ringa in ett alternativ 
    
        Jag blir bara andfådd när jag anstränger mig rejält, inte när jag tar en snabb  
         promenad eller går i uppförsbacke 
0 
  
         Jag blir andfådd när jag tar en snabb promenad eller går i uppförsbacke 1 
  
         Jag blir andfådd när jag går på slät mark i samma takt som andra personer i min  
         egen ålder.  (och/eller: )  Jag blir andfådd vid gång på slät mark så jag måste  
         stanna upp trots att jag går i min egen takt. 
2 
  
         Jag måste stanna på grund av andfåddhet efter cirka 100 m gång på slät mark 3 
  
         Jag blir andfådd när jag tvättar mig eller klär på mig 4 
 
 
 
         Frågan ej tillämplig pga nedsatt rörelseförmåga av annan anledning  99 
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23. Har Du någon gång haft Nej (  ) 
      hastigt påkommande andnöd eller andfåddhet?  Ja (  ) 
 
Om Ja på 23, besvara 24 
24. Har Du någon gång under de senaste 12 månaderna haft Nej (  ) 
      hastigt påkommande andnöd eller andfåddhet?  Ja (  ) 
 
25. Har Du någonsin haft hastigt påkommande andnöd  Nej (  ) 
      med pip eller väsningar i bröstet? Ja (  ) 
 
Om Ja på 25, besvara fråga 26-27 
26. Har Du haft hastigt påkommande andnöd med pip eller väsningar Nej (  )  
      i bröstet under de senaste 12 månaderna? Ja (  ) 
 
27. Har Du någonsin haft anfall av andnöd med pip eller väsningar i bröstet               Nej    (  ) 
     eller astmasymtom på Din arbetsplats? Ja      (  ) 
 
Astma, kronisk bronkit, emfysem och KOL 
 
28. Har Du eller har Du haft astma? Nej (  ) 
   Ja (  ) 
   Vet ej (  ) 
 
29. Har Du av läkare fått diagnosen astma? Nej (  ) 
   Ja (  ) 
   Vet ej (  ) 
   
30. Hade Du pip eller väsningar i bröstet i tidig barndom Nej (  ) 
      eller astma under barndomen? Ja (  ) 
   Vet ej (  ) 
Om Ja på någon av frågorna 28-30, 
31. Hur gammal var Du när Du första gången hade pip i bröstet   
      eller hade besvär av andnöd eller märkte av astma?          ……………………år                                                            
   
      Om Du inte minns tydligt, var det:      
      a)  Före skolåldern     (  )   
      b)  Under skolåldern men före 20 års åldern  (  )   
      c)  Mellan 20 och 30 årsåldern (  )   
      d)  Mellan 30 och 40 årsåldern (  )   
      e)  Mellan 40 och 50 årsåldern (  )   
      f)  Efter 50 årsåldern  (  )   
      g)  Minns inte alls  (  )   
 
31x. Hur gammal var du när du senast hade astmabesvär?        …………………ålder 
 
32. Har du använt astmamediciner regelbundet eller vid behov Nej (  ) 
       under de senaste 12 månaderna? Ja (  ) 
Om NEJ, besvara fråga 33. 
33. Har Du tidigare använt astmamedicin?                                                               Nej (  ) 
            Ja (  ) 
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34. Har Du av läkare fått diagnosen kronisk luftrörskatarr Nej (  ) 
       eller kronisk bronkit?  Ja (  ) 
   Vet ej (  ) 
 
35. Har Du av läkare fått diagnosen KOL? Nej (  ) 
         Ja (  ) 
   Vet ej (  ) 
 
36. Har Du av läkare fått diagnosen emfysem? Nej (  ) 
         Ja (  ) 
   Vet ej (  ) 
 
37. Har du använt mediciner regelbundet eller vid behov mot kronisk Nej (  ) 
      luftrörskatarr, KOL eller emfysem under de senaste 12 månaderna? Ja (  ) 
Om NEJ, besvara fråga 38 
 
38. Har Du tidigare använt medicin mot kronisk luftrörskatarr,  Nej (  ) 
      KOL eller emfysem                                                               Ja (  ) 
 
39. Reagerar Du på någon av följande exponeringar? 
 Inga 
besvär 
Ögon-
besvär 
Näs-
besvär 
Klåda i 
mun  och 
svalg 
Andnings- 
besvär 
Kliande 
utslag / 
eksem 
Diarré eller 
ont i 
magen 
Pollenexponering 
(gräs, björk, gråbo, 
mm) 
       
Pälsdjursexponering 
(katt, hund, häst, 
kanin, marsvin, mm) 
       
Födoämnen (fisk, 
skaldjur) 
       
Födoämnen (nötter, 
kärnförande frukter) 
       
Mjölk 
(Laktosintolerens) 
       
Mjöl  
(Glutenintolerens) 
       
 
…………………….. 
       
 
…………………….. 
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40.  Har Du, eller har Du haft, någon annan lung/luftvägssjukdom än astma, 
kronisk luftrörskatarr, KOL eller emfysem? 
Nej 
Ja 
(   ) 
(   ) 
    
 Om JA,   
    
41. Vilken/vilka?_________________________________________   
                       _________________________________________   
                      _________________________________________   
    
    
42. Har du haft Tbc Nej 
Ja, lungtbc 
Ja, annan 
tbc 
(   ) 
(   ) 
(   ) 
 
 
 
Sjukvårdsbehov pga lung- eller luftvägsbesvär eller annan sjukdom              
 
43. Har du någonsin sökt läkare eller sjukvård pga andfåddhet, andnöd eller 
pip i bröstet, hosta, slemhosta eller andra luftvägsbesvär inklusive 
förkylning? 
Nej 
Ja 
(   ) 
(   ) 
 Om Ja,    
44. Har du under senaste 12 månaderna sökt för detta beskrivet ovan? Nej 
Ja 
(   ) 
(   ) 
    
45. Har Du någon gång behövt uppsöka akutmottagning pga andningsbesvär? Nej 
Ja 
(   ) 
(   ) 
 Om Ja,    
46. Har du sökt akut under de senaste 12 månaderna? Nej 
Ja 
(   ) 
(   ) 
    
47. Har Du någon gång varit inlagd på sjukhus för andningsbesvär? Nej 
Ja 
(   ) 
(   ) 
 Om Ja,    
48. Har du varit inlagd under de senaste 12 månaderna?  Nej 
Ja 
(   ) 
(   ) 
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Frågor om allergiska näs-ögonbesvär 
 
49. Har Du eller har Du haft allergiska näsbesvär eller hösnuva? 
 
Om JA på 49 besvara 50,  
Nej 
Ja 
(   ) 
(   ) 
50. Hur gammal var Du när Du första gången hade hösnuva eller allergiska 
näsbesvär?                                                                               …………… 
 
år 
 
51. Har Du någon gång haft besvär med nysningar, rinnande näsa eller 
nästäppa utan att Du varit förkyld?  
 
Om JA på 51,,besvara fråga 52-53 
Nej 
Ja 
(   ) 
(   ) 
52. Har Du haft besvär med nysningar, rinnande näsa eller nästäppa utan att 
Du varit förkyld under senaste 12 månaderna?  
 
Nej 
Ja 
(   ) 
(   ) 
53. Har dessa näsproblem uppträtt samtidigt med kliande eller rinnande 
ögon?   
Nej 
Ja 
(   ) 
(   ) 
 
Om JA på fråga 52 
54. Vilka faktorer kan utlösa dessa näsproblem? 
  JA NEJ 
a)  Pollen från träd som björk, rönn, al m.m. (   ) (   ) 
b)  Pollen från gräs (   ) (   ) 
c)  Pälsdjur som katt, hund, häst, kanin etc (   ) (   ) 
d)  Mögel (   ) (   ) 
e)  Parfymer, lukter eller rök (   ) (   ) 
f)  Temperaturförändringar (   ) (   ) 
g)  Trycksvärta (   ) (   ) 
 
55. Har Du använt mediciner mot hösnuva/allergiska näsproblem eller 
nästäppa av icke-allergisk natur någon gång under de senaste 5 åren?  
 
Nej 
Ja 
(   ) 
(   ) 
 
56. Har Du använt mediciner mot hösnuva/allergiska näsproblem eller 
nästäppa av icke-allergisk natur någon gång under de senaste 12 mån?   
 
Nej 
Ja 
(   ) 
(   ) 
 
 
Om JA på fråga 56, besvara nedan om mediciner 
57. Antihistaminer i tablettform? 
(Aerius, Cetirizin, Clarityn, Kestine, Mizollen, Periactin, Polaramin 
prolongatum, Semprex, Tavegyl, Teldanex, Telfast, Zyrlex, Versal) 
Nej 
Ja 
(   ) 
(   ) 
    
58. Nasala steroider? 
(Becotide nasal, Flutide nasal, Nasacort, Nasonex, Rhinocort) 
 
Nej 
Ja 
(   ) 
(   ) 
59. Övrigt för näsa eller ögon? (Inkl Antasten privin, Atrovent nasal, Emadine, 
Lastin, Livostin, Lomudal, Pollyferm, Rinil, Tilavist, Zaditen, Zincfrin)  
 
Nej 
Ja 
(   ) 
(   ) 
60. Kortisonspruta (Depo-Medrol el dyl) Nej 
Ja 
(   ) 
(   ) 
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Övriga sjukdomar 
 
61. Har du eller har du haft hjärtproblem eller 
hjärtsjukdom? 
Nej  
Kärlkramp  
Hjärtinfarkt  
Hjärtsvikt   
Rytmrubbning   
Annan hjärtsjukdom 
Kranskärlsopererad/ 
(Kärlkrampsopererad) 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
    
62. Använder Du hjärt-, kärlmediciner ? 
Inklusive proppförebyggande 
Nej 
En medicin 
Två mediciner 
Tre mediciner 
Fyra mediciner eller fler 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
    
63. Har du eller har du haft högt blodtryck? 
 
Nej 
Ja 
(   ) 
(   ) 
    
64. Använder du mediciner mot högt blodtryck? Nej 
Ja 
(   ) 
(   ) 
    
65. Har du eller har du haft fönstertittarsjukan (klaudikatio, kärlkramp i benen)? 
 
Nej 
Ja 
(   ) 
(   ) 
 
66. Har du eller har du haft blodpropp eller blödning i hjärnan (TIA, stroke)? 
 
Nej 
Ja 
(   ) 
(   ) 
 
67. Har du eller har du haft förhöjda blodfetter? 
 
Nej 
Ja 
(   ) 
(   ) 
 
68. Tar Du medicin mot förhöjda blodfetter? 
 
Nej 
Ja 
(   ) 
(   ) 
 
69. Har du eller har du haft diabetes? 
 
Nej 
Ja 
(   ) 
(   ) 
 
70. Har du eller har du haft reumatisk sjukdom? 
 
Nej 
Ja 
(   ) 
(   ) 
 
71. Använder Du hormontabletter eller p-piller? (endast kvinnor) 
 
Nej 
Ja 
(   ) 
(   ) 
 
72. Har du eller har du haft halsbränna eller  
sura uppstötningar (Reflux)? 
Nej 
Ja 
(   ) 
(   ) 
 
 
 
Om JA på fråga 72 
72 b) Inträffar detta efter måltider? 
 
Nej 
Ja 
 
(   ) 
(   ) 
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73. Har du eller har du haft några andra sjukdomar än vad som nämnts ovan? 
……………………………………..   …………………………………. 
……………………………………      ………………………………. 
 
 
 
Uppväxttid 
    
74. Rökte någon av dina föräldrar eller andra anhöriga i Din hemmiljö  
under Din uppväxttid innan Du började i skolan? 
Nej  
Mor  
Far 
Annan  
(  ) 
(  ) 
(  ) 
(  ) 
    
75. Rökte Din mor då hon var gravid och väntade Dig? Nej 
Ja 
Vet ej 
(  ) 
(  ) 
(  ) 
    
76. Hade ni pälsdjur eller burfåglar i hemmiljön eller  
i den nära omgivningen under Din uppväxttid  
innan Du började i skolan?  
Nej  
Ja 
(  ) 
(  ) 
 Om Ja, vilka? Nej Ja 
                                                                                Katt 
                                                                               Hund 
                                                                               Marsvin/smågnagare 
                                                                               Häst 
                                                                               Kor 
                                                                               Renar 
                                                                               Burfåglar 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
77. Finns pälsdjur, eller fåglar i hemmiljön nu?  Nej Ja 
                                                                                Katt 
                                                                               Hund 
                                                                               Marsvin/smågnagare 
                                                                               Häst 
                                                                               Kor 
                                                                               Renar 
                                                                               Burfåglar 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
 
78. Hade Du någon allvarlig luftrörs- eller lunginfektion före skolåldern,    
t. ex. kikhosta eller krupp?   
Nej  
Ja  
Vet ej 
(  ) 
(  ) 
(  ) 
    
79. Brukade Du dela sovrum med andra barn före skolåldern? Nej  
Ja  
Vet ej 
(  ) 
(  ) 
(  ) 
    
    
80. Hur många syskon har Du eller har Du haft?                                      Antal _______  
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81. Hur många äldre syskon har Du eller har Du haft?                             Antal  
 
 
82. Vistades Du över ett år på daghem, lekskola eller barnhem tillsammans 
med andra barn före skolåldern? 
Nej  
Ja  
Vet ej 
(  ) 
(  ) 
(  ) 
 
83. Hur bodde Du mestadels före skolstart? Villa/radhus  
Lägenhet 
(  ) 
(  ) 
84. Var bodde Du mestadels före skolstart? Landsbygd 
Förort 
Stad/tätort 
 
(  ) 
(  ) 
(  ) 
85. Bodde Du mestadels i Sverige före skolstart Nej 
Ja 
(  ) 
(  ) 
 
86. 
Om Nej,  
Vilket land bodde Du mestadels i? ………………………………... 
  
 
87. Vilken var Din födelsevikt?                                                                    < 2500g 
                                                                                                           2500-3000g 
                                                                                                           3000-4000g 
                                                                                                                  >4000g  
                                                                                                                      Vet 
ej 
 (  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
88. Vad är Ditt nuvarande eller senaste yrke?                                    SEI                                                                                                                                
                                                                                              Antal år 
…………………………………………………                                                   
………
……… 
 
89. Har Du arbetat mer än 5 år i något annat yrke? Nej 
Ja 
(  ) 
(  ) 
 Om JA på fråga 89:  
 
  
90. Vilket yrke/yrken?                                                                       SEI 
                                                                                                     Antal år     
…………………………………………………                         
                                                                                                  
…………………………………………………                        SEI   
                                                                                                    Antal år 
                                                                     
……… 
……… 
 
 
……… 
……… 
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Rökning och nikotinanvändning  
    
 
91. Är Du….. Icke rökare 
Före detta  rökare 
Rökare 
(  ) 
(  ) 
(  ) 
    
92. Har Har du någonsin rökt minst ett år? 
(minst en cigarett/dag - minst en cigarr/vecka eller  
minst 30 gram tobak/månad - under minst ett års tid) 
Nej 
Ja 
(  ) 
(  ) 
    
Om Ja, 
    
93. Hur gammal var Du när Du började röka? Ålder_______  
    
Fråga 94-95 besvaras av icke-rökare och före detta rökare   
    
94. Händer det att du röker ibland? (mindre än varje vecka)                         Nej 
                          Ja 
(  ) 
(  ) 
95. Om Ja,  
Hur många cigaretter i genomsnitt per månad? 
 
Antal _________ 
 
 
Fråga 96 besvaras av före detta rökare 
    
96. Hur gammal var Du när Du slutade röka? Ålder ___ 
    
Frågorna 97-99 besvaras av rökare  
    
97. Om Du röker cigaretter, hur många röker Du  i genomsnitt per 
dag? 
 
                                                   Antal_______ 
Röker ej cigaretter 
1 –4 
5 – 14 
15 – 24 
25 eller fler 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
98. Om Du röker cigarrer/cigariller, hur många röker Du i 
genomsnitt per dag? 
Röker ej cigarr 
0 – 1 
2 - 4 
5 - > 
(  ) 
(  ) 
(  ) 
(  ) 
 
99. Om du är piprökare, hur mycket förbrukar Du i genomsnitt per 
vecka? 
Röker ej pipa 
<50g 
>50g - <100g 
>100g 
(  ) 
(  ) 
(  ) 
(  ) 
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Frågorna 100-102 besvaras av rökare och ex-rökare 
 
100.  Hur mycket har Du rökt? 
Ålder ”rökår” Cigaretter/dag Cigarrer/dag Piptobak g/vecka  
0-20      
21-40      
41-60      
60+      
      
 
101. Hur många år har Du rökt?                             Antal_________   
    
102. Uppskattade antal pack-year?                         Antal_________   
 
 
Frågorna 103-105 besvaras av icke-rökare 
 
103. Är Du eller har Du varit utsatt för rökning  Nej                       (  ) 
      i din hemmiljö?    Ja, tidigare ej nu   (  )
      Ja, nu          (  ) 
 
 
104. Är Du eller har Du varit utsatt för rökning  Nej                       (  ) 
      på arbetsplatsen?    Ja, tidigare ej nu   (  ) 
      Ja, nu           (  ) 
 
 
105. Hur mycket passiv tobaksrök har Du utsatts för under Ditt liv? 
 
                    I hemmet                   Arbete/skola/fritid 
Ålder ”rökår” timmar/dygn  ”rökår” timmar/dygn  
0-7       
8-15       
16-25       
26-40       
41-60       
61 -       
       
 
 
Saturationsmätning 
 
106. Saturation i vila                    _________%
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OLIN structured interview questions for adults (2009) 
 
 
 Date of examination:     year      month      day__________ 
 
 Interviewer  ______________________________________________ 
 
 
 
Personal data 
 
1. Name  __________________________________________________ 
 
Address __________________________________________________ 
 
Telephone number  home _____________________________________ 
 
               work  _____________________________________ 
 
 
2.  Civic registration number  ________________________________________________ 
 
 
3. Ethnicity 
 Caucasian  (  ) 
 African (  ) 
 Asian/oriental (  ) 
 Other (  ) 
 
4. Sex 
 Male (  ) 
 Female (  )  
 
       
 
5. Gradient of population density ___ 
 
 
 
 
 
The undersigned allows blood samples to be taken and saved for analysis of allergy-antibodies  
and other analyses related to allergy or asthma/COPD including genetic markers. Samples are 
registered at the Bio-bank, Norrbotten County Council (NLL). 
 
 
………………………………………………………      
Signature 
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Cough and phlegm 
 
6. Have you had longstanding cough during the last year (12 months)? No (  ) 
  Yes (  ) 
 
7. Do you usually cough or clear your throat in the morning? No (  ) 
  Yes (  ) 
 
8. Do you usually cough or clear your throat other times of the day? No (  ) 
  Yes (  ) 
 
9. Do you usually cough or bring up phlegm from your chest, or do you feel         No (  ) 
    that there is phlegm in your chest which is difficult to bring up by coughing     Yes (  ) 
    or clearing your throat? 
 
10. Do you cough or bring up phlegm (or have phlegm difficult to bring up           No (  ) 
  in spite of coughing) most days during periods of at least three months a year?   Yes (  ) 
 
If Yes,  
 
11.    Since how many years?                                                              Number of years      ____ 
 
  
 
Wheezing in the chest or whistling breathing 
 
12. Do you usually have wheezing or whistling in your chest                No (  ) 
      when breathing?                Yes (  ) 
 
13. Have you ever, now or previously, at any occasion had wheezing or whistling No (  ) 
      in your chest when breathing?  Yes (  ) 
 
14. Have you at any time during the last 12 months had wheezing or whistling   No (  )  
      in your chest? Yes (  ) 
 
If yes on 14, please answer 15 - 17  
 
15. Have you been at all breathless when the wheezing or whistling was present? No (  ) 
                                                                                                                                 Yes (  ) 
 
 
16. Have you at any time had this wheezing or whistling when you No (  ) 
     did not have a cold? Yes (  ) 
 
 
17. Do you have wheezing or whistling in your chest most days of the week?  No (  ) 
                                                                                                        Yes, periodically (  ) 
  Yes (  ) 
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Shortness of breath 
 
18.    Are you disabled (by other reasons than any heart- or lung problems)? 
             No/not relevant (  ) 
                          Yes (  ) 
If Yes,  
 
19.    For what reasons? Cerebrovascular disease (  ) 
  Muscle disease (myopathy) (  ) 
  Mobility restriction in extremities (  ) 
  Other:___________________ (  ) 
  Wheelchair-bound (  ) 
 
 
  
20. Do you ever have trouble with your breathing? No (  ) 
  Yes (  ) 
If Yes,   
 
21. Do you have this trouble   
  Continuously, so that your breathing is never quite right (  ) 
  Repeatedly, but it always gets completely better (  ) 
  Only rarely (  ) 
 
 
 
 
22. Shortness of breath at effort – MRC dyspnoea scale 
 
Which statement suites you best?                                                          encircle one alternative 
 
 I only get troubled by shortness of breath at strenuous exercise, 0 
 not when hurrying on level ground or walking up a slight hill 
 
 I get short of breath when hurrying on level ground or walking up a slight hill 1 
 
 I get short of breath when walking on level ground at the same pace as other 2 
 people of my own age. (and/or:) I get short of breath when walking on level ground so 
 that I have to stop in spite of walking at my own pace 
 
 I have to stop because of shortness of breath after some 100 m walk on level ground 3 
 
 I get short of breath when washing myself or getting dressed 4 
 
 The question not applicable because of disability for other reason 99 
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23. Have you ever had an attack of shortness of breath or breathlessness?  No (  ) 
  Yes (  ) 
If Yes on 23, go to 24 
24. Have you at any time during the last 12 months had No (  ) 
      an attack of shortness of breath or breathlessness?  Yes (  ) 
 
25. Have you ever had an attack of shortness of breath No (  ) 
      with wheezing or whistling in your chest?  Yes (  ) 
 
If Yes on 25, go to 26-27 
26. Have you had an attack of shortness of breath No (  ) 
      with wheezing or whistling in your chest during the last 12 months?  Yes (  ) 
 
27. Have you ever had an attack of shortness of breath with wheezing or No    (  ) 
      whistling in your chest or symptoms of asthma at your place of work?  Yes (  ) 
 
Asthma, chronic bronchitis, emphysema and COPD 
 
28. Do you have or have you ever had asthma? No (  ) 
   Yes (  ) 
                                                                    Don’t know (  ) 
 
29. Have you been diagnosed as having asthma by a doctor?  No (  ) 
   Yes (  ) 
                                                                    Don’t know (  ) 
   
30. Did you have wheezing or whistling in your chest No (  ) 
      in early childhood or asthma during childhood?  Yes (  ) 
                                                                    Don’t know (  ) 
If Yes on any of the questions28 – 30,  
31. How old were you when you for the first time had wheezing in your chest or 
had problems with shortness of breath or noticed asthma?     …………………years                                                            
   
      If you don´t remember clearly, was it:      
      a)  Before school age     (  )   
      b)  During school age but before 20 years of age  (  )   
      c)  Between 20 and 30 years of age (  )   
      d)  Between 30 and 40 years of age (  )   
      e)  Between 40 and 50 years of age (  )   
      f)  After 50 years of age  (  )   
      g)  Don´t remember at all  (  )   
 
31x. How old were you when you last had asthma problems …………………age 
 
32. Have you used medication for asthma regularly or as needed No (  ) 
 during the last 12 months?   Yes (  ) 
 
If NO, go to question 33. 
33. Have you previously used asthma medication?                                                       No (  ) 
            Yes (  ) 
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34. Have you been diagnosed as having chronic bronchitis by a doctor? No (  ) 
   Yes (  ) 
                                                                    Don’t know (  ) 
 
35. Have you been diagnosed as having COPD by a doctor? No (  ) 
   Yes (  ) 
                                                                    Don’t know (  ) 
 
36. Have you been diagnosed as having emphysema by a doctor? No (  ) 
   Yes (  ) 
                                                                    Don’t know (  ) 
 
37. Have you used medication regularly or as needed for  No (  ) 
chronic bronchitis, COPD or emphysema during the last 12 months?  Yes (  ) 
If NO, please answer question 38 
 
38. Have you previously used medication for chronic bronchitis, No (  ) 
      COPD or emphysema   Yes (  ) 
 
39. Do you react on any of the following exposures? 
 
No 
problems 
Eye 
problems 
Nose 
problems 
Itching of 
mouth and 
throat  
Breathing 
problems 
Itching 
eruptions/ex
cema 
Diarrhea or 
abdominal 
pains 
Exposure to pollen 
(grass, birch, 
mugwort, others) 
       
Exposure to furred 
animals (cat, dog, 
horse, rabbit, guinea 
pig, others) 
       
Food (fish, shellfish)        
Food (nuts, stone 
fruits) 
       
Milk (Lactose 
intolerance) 
       
Flour  
(Gluten intolerance) 
       
 
…………………….. 
       
 
…………………….. 
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40.  Have you or have you had any other lung/respiratory disease beside 
asthma, chronic bronchitis, COPD or emphysema? 
No 
Yes 
(   ) 
(   ) 
    
 If YES,   
    
41. Which?         _________________________________________   
                       _________________________________________   
                       _________________________________________   
    
    
42. Have you had tuberculosis (TBC) No 
Yes, pulmonary tuberculosis 
(   ) 
(   ) 
                                        Yes, other tuberculosis   (   ) 
                                                               
 
 
Need of medical attendance because of lung- or respiratory problems or other disease            
  
 
43. Have you ever consulted a physician or other medical care because of 
shortness of breath, breathlessness or wheezing in your chest, cough with 
or without phlegm or other airway problems including common cold?  
No 
Yes 
(   ) 
(   ) 
    
 If Yes,     
44. Have you during the last 12 months sought for that described above No 
Yes 
(   ) 
(   ) 
    
45. Have you ever had to visit an emergency unit because of problems with 
your breathing? 
No 
Yes 
(   ) 
(   ) 
    
 If Yes,    
46. Have you sought emergency help within the last 12 months? No 
Yes 
(   ) 
(   ) 
    
47. Have you ever been hospitalized because of problems with your 
breathing? 
No 
Yes 
(   ) 
(   ) 
  
If Yes,  
  
48. Have you been hospitalized during the last 12 months? No 
Yes 
(   ) 
(   ) 
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Questions about allergic nose-eyes problems 
 
49. Do you have or have you had any allergic nose problems or hay fever? 
 
If YES on 49, answer 50,  
No 
Yes 
(   ) 
(   ) 
50. How old were you when you for the first time had hay fever or allergic 
nose problems?…………… 
 
years 
 
51. Have you ever had problems with sneezing, runny nose or blocking of 
your nose without having a cold? 
 
If YES on 51, answer questions 52 - 53 
No 
Yes 
(   ) 
(   ) 
52. Have you during the last 12 months had problems with sneezing, runny 
nose or blocking of your nose without having a cold?  
 
No 
Yes 
(   ) 
(   ) 
53. Have these nose problems occurred along with itching or watery eyes?   No 
Yes 
(   ) 
(   ) 
 
If YES, please answer question 52 
54. What factors can trigger these nose problems? 
  YES NO 
a)  Pollen from trees like birch, mountain ash, alder etc (   ) (   ) 
b)  Pollen from grass (   ) (   ) 
c)  Furred animals like cat, dog, horse, rabbit etc. (   ) (   ) 
d)  Moulds (   ) (   ) 
e)  Perfumes, smells or smoke (   ) (   ) 
f)  Changes in temperature (   ) (   ) 
g)  Printing ink (   ) (   ) 
 
55. Have you used medication for hay fever/allergic nose problems or 
blocking of your nose of non- allergic nature at any time during the last 5 
years? 
 
No 
Yes 
(   ) 
(   ) 
 
56. Have you used medication for hay fever/allergic nose problems or 
blocking of your nose of non- allergic nature at any time during the last 
12 months?  
 
No 
Yes 
(   ) 
(   ) 
 
If YES on question 56, please answer below about medication 
57. Antihistamines as pills (peroral antihistamines)? 
(Aerius, Cetirizin, Clarityn, Kestine, Mizollen, Periactin, Polaramin 
prolongatum, Semprex, Tavegyl, Teldanex, Telfast, Zyrlex, Versal) 
No 
Yes 
(   ) 
(   ) 
    
58. Nasal steroids? 
(Becotide nasal, Flutide nasal, Nasacort, Nasonex, Rhinocort) 
 
Nej 
Ja 
(   ) 
(   ) 
59. Other for nose or eyes? (Incl. Antasten privin, Atrovent nasal, Emadine, 
Lastin, Livostin, Lomudal, Pollyferm, Rinil, Tilavist, Zaditen, Zincfrin)  
 
Nej 
Ja 
(   ) 
(   ) 
60. Corticosteroid injection  (Depo-Medrol  etc.) No 
Yes 
(   ) 
(   ) 
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Other diseases 
 
61. Do you have or have you had heart problems or heart 
disease? 
No  
Angina  
Heart attack (cardiac infarct.) 
Heart failure (insufficiency) 
Arrythmia (dysrhythmia)  
Other heart disease 
Coronary artery 
surgery/(angina surgery) 
 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
62. Do you use medication for heart-, vascular problems? 
Including for the prevention of thrombosis?   
No 
One medication 
Two medications 
Three medications 
Four medications or more 
(   ) 
(   ) 
(   ) 
(   ) 
(   ) 
    
63. Do you have or have you had high blood pressure (hypertension)? 
 
No 
Yes 
(   ) 
(   ) 
    
64. Do you use medications for high blood pressure (hypertension)? No 
Yes 
(   ) 
(   ) 
    
65. Do you have or have you had claudication (vascular spasm in the legs)? 
 
No 
Yes 
(   ) 
(   ) 
 
66. Do you have or have you had thrombosis or haemorrhage in the brain (TIA, 
stroke)? 
 
No 
Yes 
(   ) 
(   ) 
 
67. Do you have or have you had elevated blood lipids? 
 
No 
Yes 
(   ) 
(   ) 
 
68. Are you taking medications for elevated blood lipids? 
 
No 
Yes 
(   ) 
(   ) 
 
69. Do you have or have you had diabetes? 
 
No 
Yes 
(   ) 
(   ) 
 
70. Do you have or have you had rheumatic disease? 
 
No 
Yes 
(   ) 
(   ) 
 
71. Do you use hormone pills or contraceptive pills (only women) 
 
No 
Yes 
(   ) 
(   ) 
 
72. Do you have or have you had heartburn or acid reflux? 
 
No 
Yes 
(   ) 
(   ) 
 If YES on question 72   
 
 
72 b) Does this happen after meals? No 
Yes 
(   ) 
(   ) 
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73. Do you have or have you had any other diseases than what is mentioned 
above? 
……………………………………..   …………………………………. 
……………………………………      ………………………………. 
 
  
 
Childhood and adolescence 
    
74. Did any of your parents or other relatives in your home environment 
smoke during your childhood before you started school? 
No  
Mother  
Father 
Other  
(  ) 
(  ) 
(  ) 
(  ) 
    
75. Did your mother smoke while being pregnant and expecting you? No 
Yes 
Don’t 
know 
(  ) 
(  ) 
(  ) 
    
76. Did you have furred animals or cage birds in your home environment or 
in your close surroundings during your childhood before you started 
school?  
No  
Yes 
(  ) 
(  ) 
 If Yes, which ones? No Yes 
                                                                                Cat 
                                                                               Dog 
                                                                               Guinea pig/small rodent 
                                                                               Horse 
                                                                               Cows 
                                                                               Reindeer 
                                                                               Cage birds 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
77. Are there furred animals or birds in the home environment now?  No Yes 
                                                                                Cat 
                                                                               Dog 
                                                                               Guinea pig/small rodent 
                                                                               Horse 
                                                                               Cows 
                                                                               Reindeer 
                                                                               Cage birds 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
 
78. Did you have any severe bronchial- or pulmonary infections before 
school age, for instance whooping-cough or croup? 
  
No  
Yes 
Don’t 
know 
(  ) 
(  ) 
(  ) 
    
79. Did you regularly share bedroom with other children before school age? No  
Yes  
Don’t 
know 
 
(  ) 
(  ) 
(  ) 
80. How many siblings do you have or have you had?                         Number                                 _______  
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81. How many older siblings do you have or have you had?               Number                                                         
 
 
82. Did you stay more than a year in kindergarten, pre-school or orphanage 
together with other children before school age? 
No  
Yes  
Don’t 
know 
(  ) 
(  ) 
(  ) 
 
83. Before school age, how did you mostly live? House 
Apartment 
(  ) 
(  ) 
84. Before school age, where did you mostly live? Countryside 
Suburb 
Town/city  
 
(  ) 
(  ) 
(  ) 
85. Before school age, did you mostly live in Sweden? No 
Yes 
(  ) 
(  ) 
 
86. 
If No,  
In what country did you mostly live? ……………………………... 
  
 
87. What was your birth weight?                                                                < 2500g 
                                                                                                           2500-3000g 
                                                                                                           3000-4000g 
                                                                                                                  >4000g  
                                                                                                           Don’t know 
 (  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
88. What is your current or most recent occupation?                           SEI                                                                                                                                
                                                                                Number of years 
…………………………………………………                                                   
………
……… 
 
89. Have you had any other occupation for more than 5 years? No 
Yes 
(  ) 
(  ) 
 If YES on question 89:  
 
  
90. What occupation/occupations?                                                      SEI 
                                                                                Number of years 
…………………………………………………                         
                                                                                                  
…………………………………………………                           SEI   
                                                                                Number of years 
                                                                     
……… 
……… 
 
 
……… 
……… 
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Smoking and nicotine use  
    
 
91. Are you a….. Non- smoker 
Ex-smoker 
Smoker 
(  ) 
(  ) 
(  ) 
    
92. Har Have you ever smoked for at least a year? 
(at least one cigarette/day-at least one cigar/week or at least  
30 grams of tobacco/month - during at least one years’ time ) 
No 
Yes 
(  ) 
(  ) 
    
If Yes, 
    
93. How old were you when you started to smoke? Age_______  
    
Question 94-94 are answered by non-smokers and ex-smokers   
    
94. Do you smoke occasionally? (less than every week)                         No 
                       Yes 
(  ) 
(  ) 
95. If Yes,  
How many cigarettes on average per month? 
 
Number _________ 
 
 
Question 96 is answered by ex-smokers  
    
96. How old were you when you stopped smoking? Age ___ 
    
Questions 97-99 are answered by smokers  
    
97. If you smoke cigarettes, how many do you smoke per day on 
average? 
 
                                                   Number_______ 
Don´t smoke cig. 
1 –4 
5 – 14 
15 – 24 
25 or more 
(  ) 
(  ) 
(  ) 
(  ) 
(  ) 
 
98. If you smoke cigars/cigarillos, how many do you on average 
smoke per day? 
Don´t smoke cigars 
0 – 1 
2 - 4 
5 - > 
(  ) 
(  ) 
(  ) 
(  ) 
 
99. If you are a pipe smoker, how much do you on average 
consume per week? 
Don´t smoke pipe 
<50g 
>50g - <100g 
>100g 
(  ) 
(  ) 
(  ) 
(  ) 
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Questions 100-102 are answered by smokers and ex-smokers 
 
100.  How much have you smoked? 
Age ”pack-years” Cigarettes/day Cigars/day Pipe tobacco g/week  
0-20      
21-40      
41-60      
60+      
      
 
101. How many years have you smoked?               Number_________  
    
102. Estimated number of pack-years?                          Number_________  
 
Questions 103-105 are answered by non-smokers 
 
103. Are you or have you been exposed to smoking No                        (  )     
        in your home environment?   Yes, earlier, not now (  )
      Yes, now               (  ) 
 
 
104. Are you or have you been exposed to smoking No                        (  )                
in your working environment?   Yes, earlier, not now (  )
      Yes, now               (  ) 
 
 
105. How much passive tobacco smoke have you been exposed to during your life? 
 
                    At home             Work/school/spare time 
Age ”pack-years” hours/day  ”packyears” hours/day  
0-7       
8-15       
16-25       
26-40       
41-60       
61 -       
       
 
 
Saturation 
 
106. Saturation at rest                   _________%  
 
 
      
